2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T55a,To develop and validate a deep learning-based AI system for the dynamic, real-time differentiation of benign and malignant gastric ulcers during endoscopy, with the goal of enhancing diagnostic precision. This was a multicenter, retrospective study collecting endoscopic images and videos from four tertiary hospitals in China. An improved YOLOv8 model, incorporating an illumination attention module, was developed for real-time instance segmentation and classification. The dataset comprised 9,820 benign ulcer images, 1,727 malignant ulcer images, and 15,791 normal mucosa images, split into training, testing, and validation sets at an 8:1:1 ratio. Performance was evaluated based on precision, recall, specificity, and processing latency. On the validation set, the AI model achieved an overall precision, recall, and specificity of 0.91, 0.91, and 0.95, respectively. For malignant ulcer recognition specifically, the precision, recall, and specificity were 0.90, 0.91, and 0.99. The model demonstrated strong real-time performance with a latency of 8.84 ms per frame and a processing speed of 113 frames per second. The developed AI model enables accurate, real-time discrimination between benign and malignant gastric ulcers during endoscopy. It holds potential to augment clinical decision-making, standardize diagnostic quality, and optimize biopsy strategies.31:T7cf,Abstract Aim To develop and validate a deep learning-based AI system for the dynamic, real-time differentiation of benign and malignant gastric ulcers during endoscopy, with the goal of enhancing diagnostic precision. Methods This was a multicenter, retrospective study collecting endoscopic images and videos from four tertiary hospitals in China. An improved YOLOv8 model, incorporating an illumination attention module, was developed for real-time instance segmentation and classification. The dataset comprised 9,820 benign ulcer images, 1,727 malignant ulcer images, and 15,791 normal mucosa images, split into training, testing, and validation sets at an 8:1:1 ratio. Performance was evaluated based on precision, recall, specificity, and processing latency. Results On the validation set, the AI model achieved an overall precision, recall, and specificity of 0.91, 0.91, and 0.95, respectively. For malignant ulcer recognition specifically, the precision, recall, and specificity were 0.90, 0.91, and 0.99. The model demonstrated strong real-time performance with a latency of 8.84 ms per frame and a processing speed of 113 frames per second. Conclusion The developed AI model enables accurate, real-time discrimination between benign and malignant gastric ulcers during endoscopy. It holds potential to augment clinical decision-making, standardize diagnostic quality, and optimize biopsy strategies. 32:Tae9,Globally, 968 350 new cases and 659 853 deaths from gastric cancer were reported in 2022. In the US, 30 300 new cases and 10 780 deaths were estimated in 2025. Gastric cancer is more common in men, and the median age at diagnosis is 68 years. Most gastric cancers (>90%) are adenocarcinomas. Worldwide, 85% of cases arise from the stomach body or antrum and 15% from the cardia. In the US, more than 90% of patients diagnosed with gastric cancer present with symptoms such as weight loss and abdominal pain. At presentation, approximately 13% have localized disease (limited to the stomach), 15% to 25% have locally advanced disease, defined as a tumor that has spread to regional lymph nodes, and 35% to 65% have metastatic disease. Helicobacter pylori infection is a treatable risk factor associated with 90% of gastric body and antrum cancers globally. Additional modifiable risk factors include smoking, alcohol, obesity, and salt intake. In countries with high incidence such as Japan and Korea, routine endoscopic screening beginning at age 40 years is associated with improved survival. Diagnosis is made by endoscopic biopsy. Patients with localized gastric cancer are treated with surgical resection and have a 5-year relative survival rate of 75% with treatment. Patients with more advanced-stage disease should receive gastrectomy, perioperative chemotherapy with 5-fluorouracil, oxaliplatin, and docetaxel and immunotherapy (durvalumab). Metastatic or unresectable disease may be treated with chemotherapy, immunotherapy, and/or targeted therapy depending on biomarkers, including programmed cell death ligand 1 (PD-L1), human epidermal growth factor receptor 2 (ERBB2; formerly HER2 or HER2/neu), and claudin-18, isoform 2 (CLDN18.2). For PD-L1-expressing gastric cancer, adding immune checkpoint inhibitors, such as nivolumab and pembrolizumab, is associated with an additional 3 months of survival when compared with chemotherapy alone. For gastric cancers overexpressing the ERBB2 or CLDN18.2 proteins, the addition of trastuzumab or zolbetuximab, respectively, is associated with an additional 3 to 4 months' survival. Early supportive care focusing on symptom management and on nutritional and psychosocial support is associated with 3 months of survival benefit. Less than 10% of patients with metastatic gastric cancer survive more than 5 years. Approximately 30 300 new cases of gastric cancer are diagnosed annually in the US. Localized gastric cancer is treated with gastrectomy, and locally advanced disease is treated with surgery and chemoimmunotherapy. For patients with unresectable or metastatic gastric cancer, chemotherapy with immune checkpoint inhibitors and targeted therapies such as trastuzumab or zolbetuximab improves survival by several months.33:Te7b, Importance Globally, 968 350 new cases and 659 853 deaths from gastric cancer were reported in 2022. In the US, 30 300 new cases and 10 780 deaths were estimated in 2025. Observations Gastric cancer is more common in men, and the median age at diagnosis is 68 years. Most gastric cancers (&gt;90%) are adenocarcinomas. Worldwide, 85% of cases arise from the stomach body or antrum and 15% from the cardia. In the US, more than 90% of patients diagnosed with gastric cancer present with symptoms such as weight loss and abdominal pain. At presentation, approximately 13% have localized disease (limited to the stomach), 15% to 25% have locally advanced disease, defined as a tumor that has spread to regional lymph nodes, and 35% to 65% have metastatic disease. Helicobacter pylori infection is a treatable risk factor associated with 90% of gastric body and antrum cancers globally. Additional modifiable risk factors include smoking, alcohol, obesity, and salt intake. In countries with high incidence such as Japan and Korea, routine endoscopic screening beginning at age 40 years is associated with improved survival. Diagnosis is made by endoscopic biopsy. Patients with localized gastric cancer are treated with surgical resection and have a 5-year relative survival rate of 75% with treatment. Patients with more advanced-stage disease should receive gastrectomy, perioperative chemotherapy with 5-fluorouracil, oxaliplatin, and docetaxel and immunotherapy (durvalumab). Metastatic or unresectable disease may be treated with chemotherapy, immunotherapy, and/or targeted therapy depending on biomarkers, including programmed cell death ligand 1 (PD-L1), human epidermal growth factor receptor 2 ( ERBB2 ; formerly HER2 or HER2/neu ), and claudin-18, isoform 2 (CLDN18.2). For PD-L1–expressing gastric cancer, adding immune checkpoint inhibitors, such as nivolumab and pembrolizumab, is associated with an additional 3 months of survival when compared with chemotherapy alone. For gastric cancers overexpressing the ERBB2 or CLDN18.2 proteins, the addition of trastuzumab or zolbetuximab, respectively, is associated with an additional 3 to 4 months’ survival. Early supportive care focusing on symptom management and on nutritional and psychosocial support is associated with 3 months of survival benefit. Less than 10% of patients with metastatic gastric cancer survive more than 5 years. Conclusions and Relevance Approximately 30 300 new cases of gastric cancer are diagnosed annually in the US. Localized gastric cancer is treated with gastrectomy, and locally advanced disease is treated with surgery and chemoimmunotherapy. For patients with unresectable or metastatic gastric cancer, chemotherapy with immune checkpoint inhibitors and targeted therapies such as trastuzumab or zolbetuximab improves survival by several months. 34:Te5d, Background Streptococcus anginosus has been linked with an increasing risk of gastric cancer (GC) and recognised as a signature for GC screening. Objective To investigate the promotional effect of S. anginosus in terms of its metabolic interactions with the host. Design We used the functional profiles of shotgun metagenomic sequencing from stools to detect bioactive molecules relevant to S. anginosus . In vivo and in vitro experiments were used to validate the facilitation of S. anginosus to GC progression. S. anginosus clinical strains were isolated and cultivated from cancerous tissues to verify its promotion of GC via methionine production. S. anginosus ΔmetE mutant strains were constructed to confirm the critical role of metE in methionine biosynthesis. Results We verified S. anginosus facilitated GC progression in vivo and in vitro. Our functional analysis of metagenomes revealed a significant enrichment of bacterial methionine biosynthesis pathways in GC patients with high S. anginosus abundance. Methionine, identified here as one of the primary microbial metabolites derived from S. anginosus, contributed to GC progression in humans and mice. S. anginosus strains from cancerous tissues were found to promote GC via methionine production. We further observed a higher abundance and prevalence of metE gene in cancer stool metagenomes. By constructing an S. anginosus ΔmetE mutant strain, we confirmed the critical role of metE in methionine biosynthesis. Conclusion Our results elucidate the role of S. anginosus -derived methionine in GC progression, shedding light on intricate metabolic interplay between S. anginosus and host. 35:T71f,HER2 (human epidermal growth factor receptor 2) is an established therapeutic target in multiple solid tumors, particularly breast and gastric cancers. Significant advancements have been made in the development HER2-targeted therapies, including monoclonal antibodies, tyrosine kinase inhibitors, antibody-drug conjugates (ADCs), and novel bispecific antibodies. These agents have revolutionized the treatment landscape for HER2-positive metastatic cancers, resulting in improved progression-free and overall survival, and quality of life for patients. Beyond breast and gastric cancers, HER2 expression/amplification has been observed in other solid tumors, such as colorectal lung, bladder, ovarian, and biliary tract cancers, as well as offering new opportunities for personalized therapy in a larger patient population. In this review, we highlight the current state of HER2-targeted treatment strategies across HER2-expressing solid tumors, discussing the clinical efficacy, adverse event profiles, and challenges of existing therapies. We explore emerging treatment approaches, including novel agents such as HER2-targeting ADCs, combination therapies, and strategies to overcome resistance mechanisms. Additionally, we examine the role of HER2 expression heterogeneity, biomarker-driven patient selection, and diagnostic tools for patient selection and optimization of the treatment outcomes. This review also investigates ongoing challenges in expanding HER2-targeted therapies, including addressing intrinsic and acquired resistance, and tailoring strategies to low HER2-expressing or HER2-mutant tumors. Lastly, we provide insights into future directions, emphasizing the importance of precision oncology to broaden the therapeutic opportunities of HER2-targeted therapies across diverse HER2-driven malignancies.36:T759,Abstract Human epidermal growth factor receptor 2 (HER2) is an established therapeutic target in multiple solid tumors, particularly breast and gastric cancers. Significant advancements have been made in the development of HER2-targeted therapies, including monoclonal antibodies, tyrosine kinase inhibitors, antibody–drug conjugates (ADC), and novel bispecific antibodies. These agents have revolutionized the treatment landscape for HER2-positive metastatic cancers, resulting in improved progression-free and overall survival, and quality of life for patients. Beyond breast and gastric cancers, HER2 expression/amplification has been observed in other solid tumors, such as colorectal, lung, bladder, ovarian, and biliary tract cancers, offering new opportunities for personalized therapy in a larger patient population. In this review, we highlight the current state of HER2-targeted treatment strategies across HER2-expressing solid tumors, discussing the clinical efficacy, adverse event profiles, and challenges of existing therapies. We explore emerging treatment approaches, including novel agents such as HER2-targeting ADCs, combination therapies, and strategies to overcome resistance mechanisms. Additionally, we examine the role of HER2 expression heterogeneity, biomarker-driven patient selection, and diagnostic tools for patient selection and optimization of treatment outcomes. This review also investigates ongoing challenges in expanding HER2-targeted therapies, including addressing intrinsic and acquired resistance and tailoring strategies to low HER2-expressing or HER2-mutant tumors. Lastly, we provide insights into future directions, emphasizing the importance of precision oncology to broaden the therapeutic opportunities of HER2-targeted therapies across diverse HER2-driven malignancies.37:T59e,A total of 208 patients who underwent curative-intent distal gastrectomy with D2 lymphadenectomy were included in the full analysis set, with 104 patients in each group. There was no crossover between the 2 groups. Patients in the LDG group had a mean (SD) age of 61.1 (10.0) years and included 25 female patients (24.0%). Patients in the ODG group had a mean (SD) age of 60.0 (10.7) years and included 29 female patients (27.9%). No significant differences were found between the LDG and ODG groups in 30-day morbidity and mortality, including rates of any postoperative complication (22.1% vs 21.2%; P = .87) and severe complications (2.9% vs 3.8%; P > .99). The LDG group showed nonsignificant differences regarding surgical complications (21.2% vs 16.4%; P = .37) and general complications (3.9% vs 10.6%; P = .11) compared to the ODG group. The LDG group had significantly longer mean (SD) operative time (220.0 [42.4] minutes vs 153.7 [36.7] minutes; P < .001) and higher median (IQR) blood loss (80 [50-145] mL vs 50 [30-100] mL; P = .003). There were no significant differences in terms of time to the first flatus, time to oral tolerance, length of postoperative hospital stay, and time from surgery to initiation of adjuvant chemotherapy. Comorbidity was identified as an independent risk factor for postoperative complications in multivariate analysis (odds ratio, 2.42; 95% CI, 1.11-5.30; P = .03).38:Tb58,No prospective trial on laparoscopy has been specifically designed for clinical T4a gastric cancer (GC); evidence of the safety and efficacy of laparoscopy for T4a GC is currently insufficient. To compare the short-term surgical outcomes between laparoscopic distal gastrectomy (LDG) and open distal gastrectomy (ODG) with D2 lymph node dissection for patients with clinical T4a GC. The UMC-UPPERGI-01 randomized clinical trial (RCT) was a single-center, open-label, noninferiority RCT conducted at a tertiary hospital in Ho Chi Minh City, Vietnam, among patients with clinical T4a GC. The study was conducted from June 2020 to April 2025. Interim and short-term results analyses were conducted in October 2023 and June 2025, respectively. Patients were randomly assigned 1:1 to undergo LDG or ODG with D2 lymph node dissection as the full analysis set of the UMC-UPPERGI-01 trial. The procedures were performed exclusively by qualified surgeons. Short-term outcomes included surgical results, pathological characteristics, 30-day postoperative morbidity and mortality (Clavien-Dindo classification), and postoperative recovery parameters. A total of 208 patients who underwent curative-intent distal gastrectomy with D2 lymphadenectomy were included in the full analysis set, with 104 patients in each group. There was no crossover between the 2 groups. Patients in the LDG group had a mean (SD) age of 61.1 (10.0) years and included 25 female patients (24.0%). Patients in the ODG group had a mean (SD) age of 60.0 (10.7) years and included 29 female patients (27.9%). No significant differences were found between the LDG and ODG groups in 30-day morbidity and mortality, including rates of any postoperative complication (22.1% vs 21.2%; P = .87) and severe complications (2.9% vs 3.8%; P > .99). The LDG group showed nonsignificant differences regarding surgical complications (21.2% vs 16.4%; P = .37) and general complications (3.9% vs 10.6%; P = .11) compared to the ODG group. The LDG group had significantly longer mean (SD) operative time (220.0 [42.4] minutes vs 153.7 [36.7] minutes; P < .001) and higher median (IQR) blood loss (80 [50-145] mL vs 50 [30-100] mL; P = .003). There were no significant differences in terms of time to the first flatus, time to oral tolerance, length of postoperative hospital stay, and time from surgery to initiation of adjuvant chemotherapy. Comorbidity was identified as an independent risk factor for postoperative complications in multivariate analysis (odds ratio, 2.42; 95% CI, 1.11-5.30; P = .03). In the UMC-UPPERGI-01 noninferiority RCT, LDG showed comparable short-term outcomes to ODG for T4a GC. The results suggest that LDG can be recommended as an alternative to ODG by qualified surgeons for clinical T4a GC; ongoing follow-up will determine long-term oncologic outcomes. ClinicalTrials.gov Identifier: NCT04384757.39:T137e, Importance No prospective trial on laparoscopy has been specifically designed for clinical T4a gastric cancer (GC); evidence of the safety and efficacy of laparoscopy for T4a GC is currently insufficient. Objective To compare the short-term surgical outcomes between laparoscopic distal gastrectomy (LDG) and open distal gastrectomy (ODG) with D2 lymph node dissection for patients with clinical T4a GC. Design, Setting, and Participants The UMC-UPPERGI-01 randomized clinical trial (RCT) was a single-center, open-label, noninferiority RCT conducted at a tertiary hospital in Ho Chi Minh City, Vietnam, among patients with clinical T4a GC. The study was conducted from June 2020 to April 2025. Interim and short-term results analyses were conducted in October 2023 and June 2025, respectively. Interventions Patients were randomly assigned 1:1 to undergo LDG or ODG with D2 lymph node dissection as the full analysis set of the UMC-UPPERGI-01 trial. The procedures were performed exclusively by qualified surgeons. Main Outcomes and Measures Short-term outcomes included surgical results, pathological characteristics, 30-day postoperative morbidity and mortality (Clavien-Dindo classification), and postoperative recovery parameters. Results A total of 208 patients who underwent curative-intent distal gastrectomy with D2 lymphadenectomy were included in the full analysis set, with 104 patients in each group. There was no crossover between the 2 groups. Patients in the LDG group had a mean (SD) age of 61.1 (10.0) years and included 25 female patients (24.0%). Patients in the ODG group had a mean (SD) age of 60.0 (10.7) years and included 29 female patients (27.9%). No significant differences were found between the LDG and ODG groups in 30-day morbidity and mortality, including rates of any postoperative complication (22.1% vs 21.2%; P = .87) and severe complications (2.9% vs 3.8%; P &gt; .99). The LDG group showed nonsignificant differences regarding surgical complications (21.2% vs 16.4%; P = .37) and general complications (3.9% vs 10.6%; P = .11) compared to the ODG group. The LDG group had significantly longer mean (SD) operative time (220.0 [42.4] minutes vs 153.7 [36.7] minutes; P &lt; .001) and higher median (IQR) blood loss (80 [50-145] mL vs 50 [30-100] mL; P = .003). There were no significant differences in terms of time to the first flatus, time to oral tolerance, length of postoperative hospital stay, and time from surgery to initiation of adjuvant chemotherapy. Comorbidity was identified as an independent risk factor for postoperative complications in multivariate analysis (odds ratio, 2.42; 95% CI, 1.11-5.30; P = .03). Conclusions and Relevance In the UMC-UPPERGI-01 noninferiority RCT, LDG showed comparable short-term outcomes to ODG for T4a GC. The results suggest that LDG can be recommended as an alternative to ODG by qualified surgeons for clinical T4a GC; ongoing follow-up will determine long-term oncologic outcomes. Trial Registration ClinicalTrials.gov Identifier: NCT04384757 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Gastric Cancer: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Gastric Cancer (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Gastric%20Cancer\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Gastric Cancer\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Gastric%20Cancer\"}]}}"}}]],["$","$L2f",null,{"title":"Gastric Cancer: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Gastric Cancer with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1016/j.jcmgh.2026.101880","pmid":"42710618","title":"Bcl-xL Promotes Gastric Tumorigenesis via Apoptosis-Independent Wnt/β-Catenin Activation and PPARγ Suppression","journal_title":"Cellular and Molecular Gastroenterology and Hepatology","journal_issn":"2352-345X","published_at":"2026-09-09T00:00:00.000Z","url":"https://doi.org/10.1016/j.jcmgh.2026.101880","source_score":5,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-16T06:22:47.722Z","updated_at":"2026-09-16T06:22:47.722Z","tags":[{"paper_doi":"10.1016/j.jcmgh.2026.101880","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.jcmgh.2026.101880","tag_type":"brand","value":"Actos","value_numeric":null},{"paper_doi":"10.1016/j.jcmgh.2026.101880","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1016/j.jcmgh.2026.101880","tag_type":"condition","value":"Gastric Cancer","value_numeric":null},{"paper_doi":"10.1016/j.jcmgh.2026.101880","tag_type":"generic","value":"pioglitazone","value_numeric":null},{"paper_doi":"10.1016/j.jcmgh.2026.101880","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.jcmgh.2026.101880","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1016/j.jcmgh.2026.101880","tag_type":"modality","value":"Anti-Apoptotic Protein Inhibition","value_numeric":null},{"paper_doi":"10.1016/j.jcmgh.2026.101880","tag_type":"modality","value":"PPARγ Agonist","value_numeric":null},{"paper_doi":"10.1016/j.jcmgh.2026.101880","tag_type":"modality","value":"Wnt/β-Catenin Pathway Modulation","value_numeric":null},{"paper_doi":"10.1016/j.jcmgh.2026.101880","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.jcmgh.2026.101880","tag_type":"study_design","value":"Preclinical Animal Study with Epidemiological Validation","value_numeric":null},{"paper_doi":"10.1016/j.jcmgh.2026.101880","tag_type":"warning","value":"The study design is primarily preclinical (mouse models, organoids, xenografts); the epidemiological pioglitazone data is observational and may be subject to confounding. Level of evidence is set at 5 (preclinical/animal study with database validation). The impact flag 'practice_changing' reflects the novel mechanistic findings and the pioglitazone epidemiological signal, but should be interpreted cautiously pending clinical trial validation.","value_numeric":null}],"summaries":{"what_studied":"This study examined how Bcl-xL (encoded by *BCL2L1*) drives gastric tumorigenesis using APC-deficient mouse models, gastric organoids, and xenografts — with findings validated in human gastric cancer tissue and databases.","key_result":"Bcl-xL deletion reduced tumor growth and proliferation via two mechanisms: enhancing Wnt/β-catenin signaling (suppressing HNF4α and PPARγ) and dampening PPARγ-driven metabolic pathways. In human data, high *BCL2L1* expression correlated with elevated Wnt target genes and poor prognosis; high *PPARG* expression correlated with better outcomes. Epidemiological data suggested pioglitazone (a PPARγ agonist) lowered gastric cancer incidence in diabetic patients.","limitations":"Findings are based largely on mouse models (APC-deletion driven) and xenografts, which may not fully reflect the heterogeneity of human gastric cancer. The epidemiological pioglitazone data is associative and cannot establish causality. Validation in prospective human cohorts is lacking.","practice_takeaway":"BCL-xL and PPARγ may be viable therapeutic targets in gastric cancer; clinicians should be aware that pioglitazone use in diabetic patients was associated with reduced gastric cancer incidence in this epidemiological analysis, though confirmatory trials are needed before practice changes."}},{"doi":"10.1093/oncolo/oyag340","pmid":"42704682","title":"Real-world characteristics of trastuzumab deruxtecan-related interstitial lung disease in Japanese patients with breast cancer and gastric cancer","journal_title":"The Oncologist","journal_issn":"1083-7159","published_at":"2026-09-07T00:00:00.000Z","url":"https://doi.org/10.1093/oncolo/oyag340","source_score":31,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-10T06:20:06.712Z","updated_at":"2026-09-10T06:20:06.712Z","tags":[{"paper_doi":"10.1093/oncolo/oyag340","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1093/oncolo/oyag340","tag_type":"brand","value":"Enhertu","value_numeric":null},{"paper_doi":"10.1093/oncolo/oyag340","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1093/oncolo/oyag340","tag_type":"condition","value":"Breast Cancer","value_numeric":null},{"paper_doi":"10.1093/oncolo/oyag340","tag_type":"condition","value":"Gastric Cancer","value_numeric":null},{"paper_doi":"10.1093/oncolo/oyag340","tag_type":"condition","value":"Interstitial Lung Disease","value_numeric":null},{"paper_doi":"10.1093/oncolo/oyag340","tag_type":"generic","value":"trastuzumab deruxtecan","value_numeric":null},{"paper_doi":"10.1093/oncolo/oyag340","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1093/oncolo/oyag340","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1093/oncolo/oyag340","tag_type":"modality","value":"Antibody-Drug Conjugate","value_numeric":null},{"paper_doi":"10.1093/oncolo/oyag340","tag_type":"sample_size","value":"n=2801","value_numeric":2801},{"paper_doi":"10.1093/oncolo/oyag340","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1093/oncolo/oyag340","tag_type":"study_design","value":"Post-Marketing Surveillance / Post Hoc Analysis","value_numeric":null},{"paper_doi":"10.1093/oncolo/oyag340","tag_type":"warning","value":"Median age of 65 years and 75.1% female sex reflect the breast cancer–predominant population, which may skew demographic interpretation for gastric cancer subgroup.","value_numeric":null},{"paper_doi":"10.1093/oncolo/oyag340","tag_type":"warning","value":"Study population is exclusively Japanese; ILD rates and patterns may differ in non-Asian populations due to genetic or environmental factors.","value_numeric":null},{"paper_doi":"10.1093/oncolo/oyag340","tag_type":"warning","value":"The 13.6% ILD incidence rate reflects a post-marketing surveillance cohort and may not align with rates reported in randomized clinical trials.","value_numeric":null}],"summaries":{"what_studied":"This post-marketing surveillance study characterized T-DXd-related ILD in 2,801 Japanese patients with breast cancer (n=1,731) or gastric cancer (n=1,070), using an independent ILD Adjudication Committee to evaluate clinical features, imaging patterns, time to onset, and outcomes over up to 12 months from ILD onset.","key_result":"381 of 2,801 patients (13.6%) developed adjudicated T-DXd-related ILD; 78.2% were CTCAE Grade 1–2, and 7.9% (n=30) were Grade 5 (fatal). Organizing pneumonia was the dominant imaging pattern (67.7%); diffuse alveolar damage (DAD, 12.6%) was the most common pattern in fatal cases (26/30). Overall recovery rate was 83.5%, and 79.3% of corticosteroid-treated patients responded; high-dose steroids plus immunosuppressants were ineffective in 7 DAD cases.","limitations":"- Japanese-only population limits generalizability to non-Asian patients.\n- Post-marketing surveillance design lacks a control arm and may have variable case ascertainment.\n- Post hoc analysis; outcomes followed only up to 12 months from ILD onset.","practice_takeaway":"Monitor all patients on T-DXd continuously for ILD — there is no safe window, including beyond 12 months of therapy. Prompt corticosteroid initiation is effective for most cases, but DAD pattern carries high mortality and does not reliably respond to intensified immunosuppression."}},{"doi":"10.1007/s10120-026-01795-y","pmid":"42645632","title":"Prognosis-predicting factor of gastrectomy after systemic cancer therapy for cStage IVB gastric cancer","journal_title":"Gastric Cancer","journal_issn":"1436-3291","published_at":"2026-08-26T00:00:00.000Z","url":"https://doi.org/10.1007/s10120-026-01795-y","source_score":11,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-01T06:21:03.420Z","updated_at":"2026-09-01T06:21:03.420Z","tags":[{"paper_doi":"10.1007/s10120-026-01795-y","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01795-y","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01795-y","tag_type":"condition","value":"Gastric Cancer","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01795-y","tag_type":"condition","value":"Metastatic Gastric Cancer","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01795-y","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01795-y","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01795-y","tag_type":"modality","value":"Chemotherapy","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01795-y","tag_type":"modality","value":"Gastrectomy","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01795-y","tag_type":"modality","value":"Immunotherapy","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01795-y","tag_type":"modality","value":"Systemic Cancer Therapy","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01795-y","tag_type":"sample_size","value":"n=121","value_numeric":121},{"paper_doi":"10.1007/s10120-026-01795-y","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01795-y","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01795-y","tag_type":"warning","value":"Sex distribution of the 121 surgical patients is not explicitly reported in the abstract; 'mixed' is assumed based on the general gastric cancer population.","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01795-y","tag_type":"warning","value":"Specific systemic therapy regimens used (e.g., chemotherapy alone vs. chemotherapy plus immunotherapy) are referenced in background but not stratified in the reported outcomes, which may confound survival comparisons across the study period (2013–2023).","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01795-y","tag_type":"warning","value":"The 'impact_flag' of practice_changing is applied cautiously — this is a single-center retrospective study, so findings are hypothesis-generating rather than definitive. The flag reflects the clinical importance of the decision framework proposed, not a confirmed practice change.","value_numeric":null}],"summaries":{"what_studied":"This single-center retrospective study (2013–2023) evaluated outcomes of gastrectomy after systemic cancer therapy in 121 cStage IVB gastric cancer patients (79 oligometastatic, 42 polymetastatic) to identify prognostic factors for postoperative survival.","key_result":"3-year OS was 65% overall; oligometastatic disease outperformed polymetastatic (76% vs. 43%, p=0.009). Major pathological response (MPR, seen in 32%) strongly predicted survival in both groups (oligometastatic 97%, polymetastatic 89%). Patients without clinical complete response and without MPR had 3-year OS of only 50%.","limitations":"- Single-center retrospective design limits generalizability and introduces selection bias (only 7.6% of treated patients underwent gastrectomy).\n- No randomized control group; outcomes for comparable patients who did not undergo surgery are not reported.\n- The definition of oligometastatic vs. polymetastatic disease was center-specific and not validated externally.","practice_takeaway":"For stage IVB gastric cancer, surgical decision-making should go beyond technical resectability — pretreatment metastatic burden and depth of response (especially major pathological response) are key prognostic filters. Gastrectomy after systemic therapy may be appropriate in oligometastatic responders but offers limited benefit in polymetastatic patients without MPR."}},{"doi":"10.1001/jamasurg.2026.3212","pmid":"42584916","title":"National Trends and Predictors of Waiting Times for Cancer Surgery in the US","journal_title":"JAMA Surgery","journal_issn":"2168-6254","published_at":"2026-08-12T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13470436/","source_score":151,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-17T13:33:05.962Z","updated_at":"2026-08-17T13:33:05.962Z","tags":[{"paper_doi":"10.1001/jamasurg.2026.3212","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.3212","tag_type":"category","value":"Surgery","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.3212","tag_type":"condition","value":"Breast Cancer","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.3212","tag_type":"condition","value":"Colon Cancer","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.3212","tag_type":"condition","value":"Esophageal Cancer","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.3212","tag_type":"condition","value":"Gastric Cancer","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.3212","tag_type":"condition","value":"Lung Cancer","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.3212","tag_type":"condition","value":"Pancreatic Cancer","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.3212","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.3212","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.3212","tag_type":"modality","value":"Neoadjuvant Therapy","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.3212","tag_type":"modality","value":"Robotic Surgery","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.3212","tag_type":"modality","value":"Surgical Oncology","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.3212","tag_type":"sample_size","value":"n=2731059","value_numeric":2731059},{"paper_doi":"10.1001/jamasurg.2026.3212","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.3212","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.3212","tag_type":"warning","value":"Full text is under PMC embargo until August 12, 2027; summary is based solely on the abstract and results section provided.","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.3212","tag_type":"warning","value":"The impact flag 'practice_changing' is applied cautiously — the findings are large-scale and policy-relevant, but causal claims are limited by the retrospective registry design.","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.3212","tag_type":"warning","value":"The study population is 85% female, heavily driven by breast cancer cases, which may disproportionately influence aggregate trend estimates.","value_numeric":null}],"summaries":{"what_studied":"This retrospective cohort study used the National Cancer Database (2012–2023) to evaluate trends and predictors of waiting time from diagnosis to first-course therapy (up-front surgery or neoadjuvant therapy) in ~2.73 million patients with nonmetastatic stage I–III breast, colon, lung, pancreatic, gastric, or esophageal cancer who underwent definitive surgical resection.","key_result":"Median wait times increased significantly across all six cancer types from 2012–2015 to 2022–2023 (e.g., breast: 34→45 days; colon: 20→31 days; lung: 41→53 days; pancreas: 23→32 days; gastric: 35→49 days; esophageal: 38→48 days; all P<.001). Key predictors of longer delays included Medicaid insurance (5/6 cancers), lowest-quartile income (6/6), Black race (5/6), greater travel distance (4/6), care in the West (6/6), treatment at academic institutions (6/6), and use of robotic surgery (5/5 nonbreast cancers).","limitations":"- Retrospective design using administrative/registry data (National Cancer Database) limits causal inference and may not capture unmeasured confounders.\n- Full text is under embargo; detailed methodology and multivariable model specifications could not be reviewed.\n- The 85% female composition reflects heavy representation of breast cancer patients, which may skew overall pooled estimates.","practice_takeaway":"Surgical wait times for major cancers have risen steadily over a decade and are longest at academic centers and for referred, lower-income, or Black patients — clinicians and health systems should proactively track and address these gaps. Robotic surgery adoption is also independently linked to longer delays and warrants operational scrutiny."}},{"doi":"10.1128/iai.00032-26","pmid":"42439809","title":"Bad bugs mean business: gastric cancer is an intended consequence of\n Helicobacter pylori\n infection","journal_title":"Infection and Immunity","journal_issn":"0019-9567","published_at":"2026-07-13T00:00:00.000Z","url":"https://doi.org/10.1128/iai.00032-26","source_score":11,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-22T06:53:36.181Z","updated_at":"2026-08-22T06:53:36.181Z","tags":[{"paper_doi":"10.1128/iai.00032-26","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1128/iai.00032-26","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1128/iai.00032-26","tag_type":"condition","value":"Gastric Cancer","value_numeric":null},{"paper_doi":"10.1128/iai.00032-26","tag_type":"condition","value":"Gastric Metaplasia","value_numeric":null},{"paper_doi":"10.1128/iai.00032-26","tag_type":"condition","value":"Helicobacter pylori Infection","value_numeric":null},{"paper_doi":"10.1128/iai.00032-26","tag_type":"generic","value":"antibiotic eradication therapy","value_numeric":null},{"paper_doi":"10.1128/iai.00032-26","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1128/iai.00032-26","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1128/iai.00032-26","tag_type":"modality","value":"Antibiotic Therapy","value_numeric":null},{"paper_doi":"10.1128/iai.00032-26","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1128/iai.00032-26","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1128/iai.00032-26","tag_type":"warning","value":"Full page text was not extracted from the PDF; only the abstract and metadata were available. Specific cited studies, effect sizes, and trial names cited in the body of the paper could not be verified.","value_numeric":null},{"paper_doi":"10.1128/iai.00032-26","tag_type":"warning","value":"No sample size tag applied — this is a review article with no single primary study population.","value_numeric":null},{"paper_doi":"10.1128/iai.00032-26","tag_type":"warning","value":"Study design tagged as 'Narrative Review' based on abstract framing; the paper does not explicitly label itself as such.","value_numeric":null},{"paper_doi":"10.1128/iai.00032-26","tag_type":"warning","value":"The 1%–2% progression rate to gastric cancer is stated without a specific source citation in the available text.","value_numeric":null}],"summaries":{"what_studied":"This review examines whether *Helicobacter pylori* (Hp) plays an active, ongoing role in driving gastric metaplasia and carcinogenesis—or merely initiates inflammation and becomes dispensable—drawing on epidemiological, molecular, and rodent model data.","key_result":"Evidence supports an active role for Hp throughout carcinogenesis: Hp is prevalent at gastric cancer sites on molecular profiling; antibiotic eradication in patients with metaplasia prevents progression to cancer; eradication even after cancer diagnosis significantly reduces tumor recurrence. In rodent models, Hp infection accelerates carcinogenesis and increases dysplasia in metaplastic tissue.","limitations":"Full text pages were not available for extraction, so specific study counts, effect sizes, or cited trial names cannot be confirmed from the source. This is a narrative review, not a systematic review or meta-analysis, so selection bias in evidence synthesis is possible.","practice_takeaway":"Clinicians should consider Hp eradication not only as prevention in at-risk patients but also after gastric cancer diagnosis, where it may meaningfully reduce recurrence risk. Research and clinical protocols for Hp should address the full disease spectrum—from early infection through metaplasia to active cancer."}},{"doi":"10.3390/antibiotics15070673","pmid":null,"title":"Helicobacter pylori Eradication in the Era of Antibiotic Resistance: From Universal Regimens to Precision-Guided Management","journal_title":"Antibiotics","journal_issn":"2079-6382","published_at":"2026-07-09T00:00:00.000Z","url":"https://doi.org/10.3390/antibiotics15070673","source_score":17,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":false,"crossref":true,"unpaywall":true},"created_at":"2026-07-16T13:37:24.749Z","updated_at":"2026-07-16T13:37:24.749Z","tags":[{"paper_doi":"10.3390/antibiotics15070673","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.3390/antibiotics15070673","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.3390/antibiotics15070673","tag_type":"condition","value":"Gastric Cancer","value_numeric":null},{"paper_doi":"10.3390/antibiotics15070673","tag_type":"condition","value":"Helicobacter Pylori Infection","value_numeric":null},{"paper_doi":"10.3390/antibiotics15070673","tag_type":"condition","value":"Peptic Ulcer Disease","value_numeric":null},{"paper_doi":"10.3390/antibiotics15070673","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.3390/antibiotics15070673","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.3390/antibiotics15070673","tag_type":"modality","value":"Antibiotic Therapy","value_numeric":null},{"paper_doi":"10.3390/antibiotics15070673","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.3390/antibiotics15070673","tag_type":"warning","value":"No specific eradication rate numbers or head-to-head trial data are reported in the abstract; key_result reflects the directional conclusion of the review only.","value_numeric":null},{"paper_doi":"10.3390/antibiotics15070673","tag_type":"warning","value":"The impact_flag 'practice_changing' reflects the review's strong directional recommendation away from empirical therapy, but the evidence base is observational and context-dependent.","value_numeric":null},{"paper_doi":"10.3390/antibiotics15070673","tag_type":"warning","value":"This is a narrative review without systematic search methodology or meta-analytic pooling; conclusions reflect author synthesis rather than quantitative evidence grading.","value_numeric":null}],"summaries":{"what_studied":"This review evaluates the shift from empirical to precision-guided H. pylori eradication therapy, integrating evidence on antimicrobial resistance epidemiology, molecular diagnostics, susceptibility-guided treatment strategies, and barriers to personalized management.","key_result":"Evidence supports moving away from universal empirical regimens toward targeted treatment based on local resistance patterns and susceptibility testing, as rising antimicrobial resistance has progressively reduced the effectiveness of standard eradication regimens.","limitations":"As a narrative review, it does not provide pooled efficacy estimates or meta-analytic data; practical barriers highlighted (restricted resistance testing access, infrastructure gaps, economic constraints, global healthcare disparities) remain largely unresolved and limit direct clinical translation in many settings.","practice_takeaway":"Where feasible, base H. pylori treatment on local resistance surveillance or individual susceptibility testing rather than universal empirical regimens. Expanding access to rapid molecular diagnostics is key to improving eradication outcomes and preserving antibiotic effectiveness."}},{"doi":"10.1016/s1470-2045(26)00144-0","pmid":"42419336","title":"Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis","journal_title":"The Lancet Oncology","journal_issn":"1470-2045","published_at":"2026-07-08T00:00:00.000Z","url":"https://doi.org/10.1016/s1470-2045(26)00144-0","source_score":28,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-14T13:24:05.805Z","updated_at":"2026-07-14T13:24:05.805Z","tags":[{"paper_doi":"10.1016/s1470-2045(26)00144-0","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/s1470-2045(26)00144-0","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1016/s1470-2045(26)00144-0","tag_type":"condition","value":"Gastric Cancer","value_numeric":null},{"paper_doi":"10.1016/s1470-2045(26)00144-0","tag_type":"condition","value":"Peritoneal Metastases","value_numeric":null},{"paper_doi":"10.1016/s1470-2045(26)00144-0","tag_type":"generic","value":"docetaxel","value_numeric":null},{"paper_doi":"10.1016/s1470-2045(26)00144-0","tag_type":"generic","value":"oxaliplatin","value_numeric":null},{"paper_doi":"10.1016/s1470-2045(26)00144-0","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/s1470-2045(26)00144-0","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1016/s1470-2045(26)00144-0","tag_type":"modality","value":"Cytoreductive Surgery","value_numeric":null},{"paper_doi":"10.1016/s1470-2045(26)00144-0","tag_type":"modality","value":"Hyperthermic Intraperitoneal Chemotherapy","value_numeric":null},{"paper_doi":"10.1016/s1470-2045(26)00144-0","tag_type":"modality","value":"Systemic Chemotherapy","value_numeric":null},{"paper_doi":"10.1016/s1470-2045(26)00144-0","tag_type":"sample_size","value":"n=102","value_numeric":102},{"paper_doi":"10.1016/s1470-2045(26)00144-0","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/s1470-2045(26)00144-0","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1016/s1470-2045(26)00144-0","tag_type":"warning","value":"Level of evidence tagged as 2 (phase 3 RCT closed early); some would classify early-stopped RCTs at a lower level due to imprecision.","value_numeric":null},{"paper_doi":"10.1016/s1470-2045(26)00144-0","tag_type":"warning","value":"The older adult subgroup is not separately reported; median age was 60 years so most participants were general adults.","value_numeric":null},{"paper_doi":"10.1016/s1470-2045(26)00144-0","tag_type":"warning","value":"Trial was stopped early due to an unplanned commissioned futility interim analysis, which introduces the possibility of an underpowered estimate; the confidence interval is wide and does not exclude modest benefit or harm.","value_numeric":null}],"summaries":{"what_studied":"The PERISCOPE II trial randomised 102 adults with gastric adenocarcinoma and limited peritoneal metastases (Peritoneal Cancer Index <7 or positive cytology) who had not progressed on ≥3 cycles of systemic therapy, to either continued systemic therapy alone (n=51) or gastrectomy plus cytoreductive surgery and HIPEC with oxaliplatin and docetaxel (n=51), with overall survival as the primary endpoint (median follow-up 67 months).","key_result":"No survival benefit was seen with surgery plus HIPEC: median OS was 15.7 months in the experimental group vs 16.6 months in the standard group (HR 1.10, 95% CI 0.69–1.74; p=0.70). The surgical arm had substantially more harm: grade ≥3 adverse events in 42% vs 20%, serious adverse events in 44% vs 6%, and three treatment-related deaths (all in the surgical arm) within 100 days.","limitations":"- Trial closed prematurely after an unplanned interim futility analysis, leaving it underpowered for its original sample size target.\n- Small total sample (n=102) limits precision of subgroup conclusions.\n- Restricted to European tertiary centres, limiting generalisability to lower-volume settings.","practice_takeaway":"Do not add gastrectomy with cytoreductive surgery and HIPEC to systemic therapy for gastric cancer with limited peritoneal metastases — it offers no survival gain and substantially increases serious complications and treatment-related mortality. Systemic therapy alone remains the standard of care for this population."}},{"doi":"10.1007/s10120-026-01763-6","pmid":"42223869","title":"Diagnostic performance of staging laparoscopy after chemotherapy and the prognostic impact of peritoneal disease resolution in advanced gastric cancer","journal_title":"Gastric Cancer","journal_issn":"1436-3291","published_at":"2026-06-01T00:00:00.000Z","url":"https://doi.org/10.1007/s10120-026-01763-6","source_score":3,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-10T14:23:59.837Z","updated_at":"2026-06-10T14:23:59.837Z","tags":[{"paper_doi":"10.1007/s10120-026-01763-6","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01763-6","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01763-6","tag_type":"condition","value":"Gastric Cancer","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01763-6","tag_type":"condition","value":"Peritoneal Metastasis","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01763-6","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01763-6","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01763-6","tag_type":"modality","value":"Chemotherapy","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01763-6","tag_type":"modality","value":"Staging Laparoscopy","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01763-6","tag_type":"sample_size","value":"n=128","value_numeric":128},{"paper_doi":"10.1007/s10120-026-01763-6","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01763-6","tag_type":"warning","value":"'Impact_flag' set to practice_changing given the direct patient selection guidance provided, but the retrospective design and moderate sample size temper this designation.","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01763-6","tag_type":"warning","value":"Sex distribution of the study cohort is not reported in the abstract; sex tag omitted.","value_numeric":null},{"paper_doi":"10.1007/s10120-026-01763-6","tag_type":"warning","value":"The study is retrospective and single-cohort; chemotherapy regimens used are not specified in the abstract, limiting applicability to specific treatment protocols.","value_numeric":null}],"summaries":{"what_studied":"This retrospective study evaluated the diagnostic performance of post-chemotherapy staging laparoscopy (SL) in 128 advanced gastric cancer patients, and assessed the prognostic significance of peritoneal/cytologic (P/CY) disease resolution after chemotherapy.","key_result":"Post-chemotherapy SL positivity rate was 38.3%. Newly detected peritoneal disease occurred in only 2.8–5.6% of initially negative patients. Among 92 patients with pre-chemotherapy peritoneal disease, true P/CY resolution was 37.0%. P/CY resolution conferred markedly better survival (median 53.7 vs. 21.5 months); persistent P/CY positivity was an independent adverse prognostic factor.","limitations":"- Retrospective single-cohort design limits causal inference and generalizability.\n- False-negative SL findings were identified, meaning true peritoneal disease rates may be underestimated.\n- Risk of early peritoneal recurrence after a negative post-chemotherapy SL requires careful clinical interpretation.","practice_takeaway":"Post-chemotherapy staging laparoscopy is most valuable for patients who had peritoneal disease at diagnosis — it identifies the ~37% who achieve P/CY resolution and may benefit from treatment escalation. For initially peritoneal-negative patients, routine post-chemotherapy SL has limited yield but false-negatives and early recurrence risk still warrant vigilance."}},{"doi":"10.1111/jgh.70474","pmid":"42216255","title":"Re‐Evaluating the\n J‐GESS Score\n : A 5‐Year Unified Risk Prediction Model for Gastric Cancer and Esophageal Squamous Cell Carcinoma","journal_title":"Journal of Gastroenterology and Hepatology","journal_issn":"0815-9319","published_at":"2026-05-29T00:00:00.000Z","url":"https://doi.org/10.1111/jgh.70474","source_score":1,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-06T13:22:54.608Z","updated_at":"2026-06-06T13:22:54.608Z","tags":[{"paper_doi":"10.1111/jgh.70474","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1111/jgh.70474","tag_type":"condition","value":"Esophageal Squamous Cell Carcinoma","value_numeric":null},{"paper_doi":"10.1111/jgh.70474","tag_type":"condition","value":"Gastric Cancer","value_numeric":null},{"paper_doi":"10.1111/jgh.70474","tag_type":"modality","value":"Risk Scoring Tool","value_numeric":null},{"paper_doi":"10.1111/jgh.70474","tag_type":"study_design","value":"Risk Prediction Model Validation Study","value_numeric":null},{"paper_doi":"10.1111/jgh.70474","tag_type":"warning","value":"Only the paper title, DOI, journal, and publication date were provided — no abstract, methods, results, or full text were included. All summary fields requiring specific data (key results, sample size, limitations, practice takeaway) have been set to null due to insufficient source content. A full extraction requires access to the paper body.","value_numeric":null}],"summaries":{"what_studied":"This study re-evaluated the J-GESS score as a unified 5-year risk prediction model for both gastric cancer (GC) and esophageal squamous cell carcinoma (ESCC), assessing its predictive performance in a defined population."}},{"doi":"10.1038/s41571-026-01156-9","pmid":"42141214","title":"Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons","journal_title":"Nature Reviews Clinical Oncology","journal_issn":"1759-4774","published_at":"2026-05-15T00:00:00.000Z","url":"https://doi.org/10.1038/s41571-026-01156-9","source_score":27,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-19T13:22:55.343Z","updated_at":"2026-05-19T13:22:55.343Z","tags":[{"paper_doi":"10.1038/s41571-026-01156-9","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41571-026-01156-9","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1038/s41571-026-01156-9","tag_type":"condition","value":"Gastric Cancer","value_numeric":null},{"paper_doi":"10.1038/s41571-026-01156-9","tag_type":"condition","value":"Oesophageal Adenocarcinoma","value_numeric":null},{"paper_doi":"10.1038/s41571-026-01156-9","tag_type":"condition","value":"Oesophageal Squamous Cell Carcinoma","value_numeric":null},{"paper_doi":"10.1038/s41571-026-01156-9","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1038/s41571-026-01156-9","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1038/s41571-026-01156-9","tag_type":"modality","value":"Chemoradiotherapy","value_numeric":null},{"paper_doi":"10.1038/s41571-026-01156-9","tag_type":"modality","value":"Endoscopic Mucosal Resection / Endoscopic Submucosal Dissection","value_numeric":null},{"paper_doi":"10.1038/s41571-026-01156-9","tag_type":"modality","value":"Surgical Resection","value_numeric":null},{"paper_doi":"10.1038/s41571-026-01156-9","tag_type":"modality","value":"Systemic Anti-Cancer Therapy","value_numeric":null},{"paper_doi":"10.1038/s41571-026-01156-9","tag_type":"sample_size","value":"n=20582","value_numeric":20582},{"paper_doi":"10.1038/s41571-026-01156-9","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41571-026-01156-9","tag_type":"study_design","value":"National Audit / Registry Study","value_numeric":null},{"paper_doi":"10.1038/s41571-026-01156-9","tag_type":"warning","value":"The audit covers diagnoses up to end of 2023, published September 2025; some indicators (e.g., 1-year survival) use data only up to end of 2022 to allow adequate follow-up.","value_numeric":null},{"paper_doi":"10.1038/s41571-026-01156-9","tag_type":"warning","value":"The paper's metadata and DOI reference a Nature Reviews Clinical Oncology article on perioperative GEA treatment, but the actual full text is the 2025 NOGCA State of the Nation Audit Report—a UK national audit of routine clinical data—not the review article described in the abstract. Summaries and tags reflect the audit report content.","value_numeric":null},{"paper_doi":"10.1038/s41571-026-01156-9","tag_type":"warning","value":"Welsh data quality is materially compromised by an ongoing cancer informatics system transition, and several key indicators could not be reported for Wales.","value_numeric":null}],"summaries":{"what_studied":"A national audit (NOGCA) evaluating quality-of-care indicators for 20,582 people diagnosed with oesophageal or gastric (OG) cancer in England and Wales between 1 January 2022 and 31 December 2023, covering emergency diagnosis rates, treatment waiting times, curative and palliative treatment uptake, surgical outcomes, and CNS access.","key_result":"Over one-third of patients were diagnosed at stage 4 (38% England, 32% Wales), with no improvement over five years. Curative treatment was received by 53% (England) and 31% (Wales) of stage 1–3 patients. Post-surgical 90-day survival was 96.6% (England) and 95.6% (Wales); 1-year survival was 84.2% and 85.7%, respectively. Among stage 4 patients starting palliative SACT in England, 4.3% died within 30 days and 16.7% within 90 days.","limitations":"- Pathology data (resection margins, lymph node yield) were largely unavailable for England, limiting surgical quality benchmarking.\n- CNS contact data were missing for 37% of English patients and entirely absent for Wales.\n- Welsh palliative SACT data were unreliable due to a new cancer informatics system rollout, precluding reporting of palliative chemotherapy outcomes for Wales.","practice_takeaway":"More than 1 in 3 OG cancer patients still present at stage 4—clinicians and Cancer Alliances should prioritise earlier detection pathways and risk-stratification tools in primary care. For stage 4 patients starting palliative SACT, a 16.7% 90-day mortality rate underscores the need for rigorous fitness assessment (e.g., Clinical Frailty Scale) and frank best supportive care discussions before initiating treatment."}},{"doi":"10.1186/s12876-026-04848-9","pmid":"42082915","title":"Development and validation of a real-time AI model for differentiating benign and malignant gastric ulcers : a multicenter retrospective study","journal_title":"BMC Gastroenterology","journal_issn":"1471-230X","published_at":"2026-05-05T00:00:00.000Z","url":"https://doi.org/10.1186/s12876-026-04848-9","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-05-10","doi":"10.1186/s12876-026-04848-9","days":"7","issn":"1471-230X","rank":"8","field":"Clinical Medicine","score":"7","category":"Gastroenterology & Hepatology","categories":["Gastroenterology & Hepatology"],"_categories":["Gastroenterology & Hepatology"]},"pubmed":{"doi":"10.1186/s12876-026-04848-9","title":"Development and validation of a real-time AI model for differentiating benign and malignant gastric ulcers : a multicenter retrospective study.","journal":"BMC gastroenterology","methods":"","results":"On the validation set, the AI model achieved an overall precision, recall, and specificity of 0.91, 0.91, and 0.95, respectively. For malignant ulcer recognition specifically, the precision, recall, and specificity were 0.90, 0.91, and 0.99. The model demonstrated strong real-time performance with a latency of 8.84 ms per frame and a processing speed of 113 frames per second.","abstract":"$30","keywords":["Artificial intelligence","Benign and malignant differentiation","Deep learning","Endoscopic diagnosis","Gastric ulcer"],"pubmed_id":"42082915","conclusions":"The developed AI model enables accurate, real-time discrimination between benign and malignant gastric ulcers during endoscopy. It holds potential to augment clinical decision-making, standardize diagnostic quality, and optimize biopsy strategies.","publication_date":"2026-05-05T00:00:00"},"crossref":{"DOI":"10.1186/s12876-026-04848-9","URL":"https://doi.org/10.1186/s12876-026-04848-9","ISSN":["1471-230X"],"link":[{"URL":"https://link.springer.com/article/10.1186/s12876-026-04848-9","content-type":"text/html","content-version":"vor","intended-application":"text-mining"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Development and validation of a real-time AI model for differentiating benign and malignant gastric ulcers : a multicenter retrospective study"],"author":[{"given":"Yibo","family":"Tan","sequence":"first","affiliation":[]},{"given":"Yongjun","family":"Wu","sequence":"additional","affiliation":[]},{"given":"Mei","family":"Yang","sequence":"additional","affiliation":[]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[]},{"given":"Xiaofei","family":"Bi","sequence":"additional","affiliation":[]},{"given":"Song","family":"He","sequence":"additional","affiliation":[]},{"given":"Zhihang","family":"Zhou","sequence":"additional","affiliation":[]},{"given":"Junyu","family":"Lu","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2026,5,4]]},"member":"297","prefix":"10.1186","source":"Crossref","volume":null,"created":{"date-time":"2026-05-04T04:53:56Z","timestamp":1777870436000,"date-parts":[[2026,5,4]]},"indexed":{"date-time":"2026-05-05T02:58:12Z","timestamp":1777949892396,"date-parts":[[2026,5,5]]},"license":[{"URL":"https://creativecommons.org/licenses/by/4.0","start":{"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000,"date-parts":[[2026,5,4]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://creativecommons.org/licenses/by/4.0","start":{"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000,"date-parts":[[2026,5,4]]},"delay-in-days":0,"content-version":"am"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://link.springer.com/10.1186/s12876-026-04848-9"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"ArticleHistory","label":"Article History"},"label":"Received","order":1,"value":"3 February 2026"},{"name":"accepted","group":{"name":"ArticleHistory","label":"Article History"},"label":"Accepted","order":2,"value":"15 April 2026"},{"name":"first_online","group":{"name":"ArticleHistory","label":"Article History"},"label":"First Online","order":3,"value":"4 May 2026"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"},"order":1},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"},"order":2,"value":"The study was conducted in accordance with the Declaration of Helsinki (as revised in 2024). The study protocol, including the request for waiver of informed consent, was initially reviewed and approved by the Institutional Review Board (The Ethics Committee of the Second Affiliated Hospital of Chongqing Medical University; Approval No. 2024 Ethical Review No.129). The requirement for informed consent was waived by the Institutional Review Boards due to the retrospective nature of the study and the use of fully anonymized data."},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"},"order":3,"value":"Not applicable."},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"},"order":4,"value":"The authors declare no competing interests."}],"deposited":{"date-time":"2026-05-04T04:53:57Z","timestamp":1777870437000,"date-parts":[[2026,5,4]]},"issn-type":[{"type":"electronic","value":"1471-230X"}],"published":{"date-parts":[[2026,5,4]]},"publisher":"Springer Science and Business Media LLC","reference":null,"short-title":[],"update-policy":"https://doi.org/10.1007/springer_crossmark_policy","alternative-id":["4848"],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"original-title":[],"container-title":["BMC Gastroenterology"],"reference-count":0,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,5,4]]},"references-count":0,"short-container-title":["BMC Gastroenterol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1186/s12876-026-04848-9","is_oa":true,"title":"Development and validation of a real-time AI model for differentiating benign and malignant gastric ulcers : a multicenter retrospective study","updated":"2026-05-05T11:59:32+00:00","published_date":"2026-05-04","best_oa_location":{"url":"https://doi.org/10.1186/s12876-026-04848-9","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1186/s12876-026-04848-9"}}},"created_at":"2026-05-14T13:23:01.287Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1186/s12876-026-04848-9","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1186/s12876-026-04848-9","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1186/s12876-026-04848-9","tag_type":"condition","value":"Gastric Cancer","value_numeric":null},{"paper_doi":"10.1186/s12876-026-04848-9","tag_type":"condition","value":"Gastric Ulcer","value_numeric":null},{"paper_doi":"10.1186/s12876-026-04848-9","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1186/s12876-026-04848-9","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1186/s12876-026-04848-9","tag_type":"modality","value":"Artificial Intelligence / Deep Learning","value_numeric":null},{"paper_doi":"10.1186/s12876-026-04848-9","tag_type":"modality","value":"Endoscopy","value_numeric":null},{"paper_doi":"10.1186/s12876-026-04848-9","tag_type":"sample_size","value":"n=27338","value_numeric":27338},{"paper_doi":"10.1186/s12876-026-04848-9","tag_type":"study_design","value":"Diagnostic Accuracy Study","value_numeric":null},{"paper_doi":"10.1186/s12876-026-04848-9","tag_type":"study_design","value":"Retrospective Multicenter Validation Study","value_numeric":null},{"paper_doi":"10.1186/s12876-026-04848-9","tag_type":"warning","value":"Design label approximated; this is a retrospective, image-based diagnostic model development/validation study.","value_numeric":null},{"paper_doi":"10.1186/s12876-026-04848-9","tag_type":"warning","value":"Metrics are from the study’s validation set; no prospective clinical testing was reported.","value_numeric":null},{"paper_doi":"10.1186/s12876-026-04848-9","tag_type":"warning","value":"No direct comparison to endoscopist diagnostic accuracy is provided, making clinical added value difficult to assess.","value_numeric":null},{"paper_doi":"10.1186/s12876-026-04848-9","tag_type":"warning","value":"Sample size reflects number of images; the number of videos/patients was not reported.","value_numeric":null},{"paper_doi":"10.1186/s12876-026-04848-9","tag_type":"warning","value":"Sample size reflects total images, not unique patients — patient-level N is not reported, which may inflate performance metrics.","value_numeric":null},{"paper_doi":"10.1186/s12876-026-04848-9","tag_type":"warning","value":"Study is from four Chinese tertiary centers only; performance in community or non-Asian settings is unknown.","value_numeric":null},{"paper_doi":"10.1186/s12876-026-04848-9","tag_type":"warning","value":"The dataset imbalance (benign images ~5.7× more than malignant) could bias recall estimates; mitigation strategies are not described in the abstract.","value_numeric":null}],"summaries":{"limitations":"Retrospective, image-based dataset from four centers without reported patient-level outcomes. Performance was reported only on the study’s validation set.","what_studied":"A multicenter retrospective study developed and validated an improved YOLOv8 AI to distinguish benign from malignant gastric ulcers in real time during endoscopy. The dataset contained 27,338 images (9,820 benign ulcers; 1,727 malignant ulcers; 15,791 normal mucosa) split 8:1:1, with performance assessed by precision, recall, specificity, and latency.","key_result":"On the validation set, overall precision, recall, and specificity were 0.91, 0.91, and 0.95; for malignant ulcers, precision, recall, and specificity were 0.90, 0.91, and 0.99. Real-time performance showed 8.84 ms/frame latency and 113 frames/second processing speed.","practice_takeaway":"In this multicenter dataset, the AI achieved high accuracy and real-time speed for classifying gastric ulcers, suggesting potential to assist endoscopic decision-making and biopsy strategy selection."}},{"doi":"10.1111/den.70159","pmid":"42067512","title":"Impact of Artificial Intelligence‐Assisted Endoscopy on Screening for Upper Gastrointestinal Cancer in a Large‐Scale Health Screening Facility","journal_title":"Digestive Endoscopy","journal_issn":"0915-5635","published_at":"2026-05-01T00:00:00.000Z","url":"https://doi.org/10.1111/den.70159","source_score":21,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-22T13:22:24.461Z","updated_at":"2026-05-22T13:22:24.461Z","tags":[{"paper_doi":"10.1111/den.70159","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/den.70159","tag_type":"brand","value":"EW10-EG01","value_numeric":null},{"paper_doi":"10.1111/den.70159","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1111/den.70159","tag_type":"condition","value":"Esophageal Cancer","value_numeric":null},{"paper_doi":"10.1111/den.70159","tag_type":"condition","value":"Gastric Cancer","value_numeric":null},{"paper_doi":"10.1111/den.70159","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1111/den.70159","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1111/den.70159","tag_type":"modality","value":"Artificial Intelligence-Assisted Endoscopy","value_numeric":null},{"paper_doi":"10.1111/den.70159","tag_type":"modality","value":"Computer-Aided Detection (CADe)","value_numeric":null},{"paper_doi":"10.1111/den.70159","tag_type":"sample_size","value":"n=49980","value_numeric":49980},{"paper_doi":"10.1111/den.70159","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/den.70159","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1111/den.70159","tag_type":"warning","value":"Absolute cancer case numbers are small (24 GC and 10 EC post-PSM), so effect estimates carry wide uncertainty despite statistical significance.","value_numeric":null},{"paper_doi":"10.1111/den.70159","tag_type":"warning","value":"The AI system (FUJIFILM EW10-EG01) used in this study is a specific proprietary device; results may not generalize to other AI endoscopy platforms.","value_numeric":null},{"paper_doi":"10.1111/den.70159","tag_type":"warning","value":"The impact_flag 'practice_changing' is applied cautiously — this is a single-center retrospective study, and prospective multicenter validation is still needed.","value_numeric":null},{"paper_doi":"10.1111/den.70159","tag_type":"warning","value":"The non-AI period used a mix of older (non-LCI) and newer endoscopic systems, introducing hardware confounding that PSM could not fully address.","value_numeric":null}],"summaries":{"what_studied":"This retrospective cohort study evaluated whether AI-assisted upper GI endoscopy (FUJIFILM EW10-EG01 CADe system) improved gastric and esophageal cancer detection rates (CDR), biopsy rates, and biopsy PPV compared to non-AI endoscopy at a single large Japanese screening center (April 2021–March 2024), using propensity score matching (PSM) across 49,980 examinations.","key_result":"After PSM (17,662 pairs), AI-assisted endoscopy significantly raised gastric cancer CDR (0.10% vs. 0.03%, p<0.05) and combined biopsy PPV for gastric and esophageal cancer (4.84% vs. 2.16%, p<0.05). Overall CDR for GC+EC was 0.14% (AI) vs. 0.06% (non-AI). Esophageal cancer CDR did not differ significantly. Examination time was slightly shorter with AI (7.22 vs. 7.37 min, p<0.0001). AI benefit on CDR was most pronounced among less experienced endoscopists (5–9 years).","limitations":"- Retrospective design with residual confounding: equipment differed between periods (older systems lacking LCI in ~20% of non-AI procedures), and image-enhancement mode use varied by endoscopist.\n- Single-center study in Japan with high H. pylori prevalence; findings may not generalize to low-GC-prevalence regions.\n- Very low absolute case counts (especially esophageal cancer, n=10 post-PSM) limit statistical power for EC-specific conclusions.","practice_takeaway":"AI-assisted CADe endoscopy roughly tripled gastric cancer detection rates in a high-volume screening setting without prolonging exam time, with the greatest benefit seen in less experienced endoscopists. Clinicians in high-GC-prevalence settings should consider integrating real-time AI endoscopy support, particularly where less experienced staff perform screenings."}},{"doi":"10.1002/cncr.70316","pmid":"41937496","title":"Increasing incidence and changing distribution of primary cancers in therapy‐related acute myeloid leukemia: A population‐based study in Osaka, Japan, 1990–2020","journal_title":"Cancer","journal_issn":"0008-543X","published_at":"2026-04-06T00:00:00.000Z","url":"https://doi.org/10.1002/cncr.70316","source_score":120,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-07T22:49:30.338Z","updated_at":"2026-05-07T22:49:30.338Z","tags":[{"paper_doi":"10.1002/cncr.70316","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1002/cncr.70316","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1002/cncr.70316","tag_type":"condition","value":"Acute Myeloid Leukemia","value_numeric":null},{"paper_doi":"10.1002/cncr.70316","tag_type":"condition","value":"Breast Cancer","value_numeric":null},{"paper_doi":"10.1002/cncr.70316","tag_type":"condition","value":"Colorectal Cancer","value_numeric":null},{"paper_doi":"10.1002/cncr.70316","tag_type":"condition","value":"Gastric Cancer","value_numeric":null},{"paper_doi":"10.1002/cncr.70316","tag_type":"condition","value":"Hematological Malignancy","value_numeric":null},{"paper_doi":"10.1002/cncr.70316","tag_type":"condition","value":"Therapy-Related Acute Myeloid Leukemia","value_numeric":null},{"paper_doi":"10.1002/cncr.70316","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1002/cncr.70316","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1002/cncr.70316","tag_type":"sample_size","value":"n=9841","value_numeric":9841},{"paper_doi":"10.1002/cncr.70316","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1002/cncr.70316","tag_type":"study_design","value":"Population-Based Cohort Study","value_numeric":null},{"paper_doi":"10.1002/cncr.70316","tag_type":"warning","value":"tAML definition relies on documented prior treatment (chemo/RT) in the registry; under-recording of prior therapy could underestimate true tAML burden.","value_numeric":null},{"paper_doi":"10.1002/cncr.70316","tag_type":"warning","value":"The registry data do not specify which chemotherapy agents or radiation doses drove tAML risk, limiting mechanistic interpretation.","value_numeric":null},{"paper_doi":"10.1002/cncr.70316","tag_type":"warning","value":"The study is restricted to Osaka, Japan; incidence trends and primary cancer distribution may not generalize to other ethnic or geographic populations.","value_numeric":null}],"summaries":{"what_studied":"Population-based study of 9,841 AML patients in Osaka, Japan (1990–2020) examining 30-year trends in therapy-related AML (tAML) incidence and the distribution of preceding primary cancers that were treated with chemotherapy and/or radiotherapy.","key_result":"636 of 9,841 AML patients (6.5%) had tAML; annual incidence nearly tripled from 0.13 to 0.36 per 100,000 population, with an adjusted incidence rate ratio of 1.28 per 10 years (95% CI 1.05–1.55). The most common primary cancer was hematological malignancy (23.1%), followed by breast cancer (14.6%), colorectal cancer (11.5%), and gastric cancer (8.7%); breast cancer rose sharply while gastric cancer declined over time.","limitations":"Single-region registry (Osaka) limits generalizability to other Japanese or global populations. Specific chemotherapy agents and radiotherapy doses were not captured, preventing attribution of tAML risk to particular regimens. No survival or outcome data reported, so clinical prognosis cannot be assessed.","practice_takeaway":"Clinicians treating breast cancer and hematological malignancies should be aware of rising tAML risk, as these are now the leading contributors to tAML in Japan. Long-term cancer survivors who received cytotoxic therapy warrant vigilance for hematologic changes that may signal tAML."}},{"doi":"10.1001/jama.2026.0663","pmid":"41848693","title":"Treatment of\n Helicobacter pylori\n Infection","journal_title":"JAMA","journal_issn":"0098-7484","published_at":"2026-03-18T00:00:00.000Z","url":"https://doi.org/10.1001/jama.2026.0663","source_score":163,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-15T13:23:00.545Z","updated_at":"2026-05-15T13:23:00.545Z","tags":[{"paper_doi":"10.1001/jama.2026.0663","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jama.2026.0663","tag_type":"brand","value":"Vonoprazan","value_numeric":null},{"paper_doi":"10.1001/jama.2026.0663","tag_type":"category","value":"Medicine, General & Internal","value_numeric":null},{"paper_doi":"10.1001/jama.2026.0663","tag_type":"condition","value":"Chronic Gastritis","value_numeric":null},{"paper_doi":"10.1001/jama.2026.0663","tag_type":"condition","value":"Gastric Cancer","value_numeric":null},{"paper_doi":"10.1001/jama.2026.0663","tag_type":"condition","value":"Helicobacter pylori Infection","value_numeric":null},{"paper_doi":"10.1001/jama.2026.0663","tag_type":"condition","value":"Peptic Ulcer Disease","value_numeric":null},{"paper_doi":"10.1001/jama.2026.0663","tag_type":"generic","value":"rifabutin","value_numeric":null},{"paper_doi":"10.1001/jama.2026.0663","tag_type":"generic","value":"vonoprazan","value_numeric":null},{"paper_doi":"10.1001/jama.2026.0663","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jama.2026.0663","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1001/jama.2026.0663","tag_type":"modality","value":"Antibiotic Therapy","value_numeric":null},{"paper_doi":"10.1001/jama.2026.0663","tag_type":"modality","value":"Potassium-Competitive Acid Blocker","value_numeric":null},{"paper_doi":"10.1001/jama.2026.0663","tag_type":"study_design","value":"Clinical Practice Guideline Synopsis","value_numeric":null},{"paper_doi":"10.1001/jama.2026.0663","tag_type":"warning","value":"Age group tagged as 'adult' by convention for gastroenterology H. pylori guidelines, but the synopsis does not explicitly state the target population.","value_numeric":null},{"paper_doi":"10.1001/jama.2026.0663","tag_type":"warning","value":"Full text is paywalled; summary is based solely on the abstract and visible publisher page text. Specific regimen details, dosing, evidence grades, and clinical tables from the synopsis are not available for extraction.","value_numeric":null},{"paper_doi":"10.1001/jama.2026.0663","tag_type":"warning","value":"Level of evidence set to '1' reflecting guideline-level evidence synthesis, but individual underlying study levels were not accessible.","value_numeric":null}],"summaries":{"what_studied":"A JAMA Clinical Guidelines Synopsis summarizing the American College of Gastroenterology's 2024 guideline on treatment of *Helicobacter pylori* infection, with focus on new regimens addressing increasing antibiotic resistance.","key_result":"New treatment regimens incorporate antibiotics such as rifabutin or more potent acid-suppressing agents including potassium-competitive acid blockers (PCABs) such as vonoprazan to address rising antibiotic resistance.","limitations":"Only the abstract and publisher page text are available; the full guideline synopsis content, evidence tables, and specific regimen details are behind a paywall and could not be reviewed.","practice_takeaway":"Consider rifabutin-based regimens or vonoprazan (a PCAB) as part of *H. pylori* eradication therapy, especially in settings with high antibiotic resistance. Clinicians should consult the full ACG 2024 guideline for specific regimen selection and sequencing."}},{"doi":"10.1001/jama.2025.20034","pmid":"41499132","title":"Gastric Cancer","journal_title":"JAMA","journal_issn":"0098-7484","published_at":"2026-01-07T00:00:00.000Z","url":"https://doi.org/10.1001/jama.2025.20034","source_score":190,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-01-12","doi":"10.1001/jama.2025.20034","days":"7","issn":"0098-7484","rank":"9","field":"Clinical Medicine","score":"190","category":"Medicine, General & Internal","categories":["Medicine, General & Internal"],"_categories":["Medicine, General & Internal"]},"pubmed":{"doi":"10.1001/jama.2025.20034","title":"Gastric Cancer: A Review.","journal":"JAMA","methods":"","results":"","abstract":"$32","keywords":[],"pubmed_id":"41499132","conclusions":"","publication_date":"2026-01-07T00:00:00"},"crossref":{"DOI":"10.1001/jama.2025.20034","URL":"https://doi.org/10.1001/jama.2025.20034","ISSN":["0098-7484"],"link":[{"URL":"https://jamanetwork.com/journals/jama/articlepdf/2843616/jama_patel_2026_rv_250035_1767115812.09443.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Gastric Cancer"],"author":[{"given":"Anuj Kishor","family":"Patel","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts"}]},{"given":"Nilay S.","family":"Sethi","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts"}]},{"given":"Haeseong","family":"Park","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts"}]}],"issued":{"date-parts":[[2026,1,7]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2026-01-07T16:31:01Z","timestamp":1767803461000,"date-parts":[[2026,1,7]]},"indexed":{"date-time":"2026-01-08T04:04:15Z","timestamp":1767845055062,"date-parts":[[2026,1,8]]},"subject":[],"abstract":"$33","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jama/fullarticle/2843616"}},"subtitle":["A Review"],"deposited":{"date-time":"2026-01-07T16:31:02Z","timestamp":1767803462000,"date-parts":[[2026,1,7]]},"issn-type":[{"type":"print","value":"0098-7484"}],"published":{"date-parts":[[2026,1,7]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.3322/caac.21834","key":"jrv250035r1","year":"2024","issue":"3","author":"Bray","volume":"74","first-page":"229","unstructured":null,"article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","journal-title":"CA Cancer J Clin","doi-asserted-by":"publisher"},{"DOI":"10.3322/caac.21871","key":"jrv250035r2","year":"2025","issue":"1","author":"Siegel","volume":"75","first-page":"10","unstructured":null,"article-title":"Cancer statistics, 2025.","journal-title":"CA Cancer J Clin","doi-asserted-by":"publisher"},{"DOI":"10.1158/1055-9965.EPI-13-1057","key":"jrv250035r3","year":"2014","issue":"5","author":"Karimi","volume":"23","first-page":"700","unstructured":null,"article-title":"Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention.","journal-title":"Cancer Epidemiol Biomarkers Prev","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.gie.2011.04.038","key":"jrv250035r4","year":"2011","issue":"3","author":"Ahn","volume":"74","first-page":"485","unstructured":null,"article-title":"Endoscopic and oncologic outcomes after endoscopic resection for early gastric cancer: 1370 cases of absolute and extended indications.","journal-title":"Gastrointest Endosc","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2025.10218","key":"jrv250035r5","year":"2025","issue":"15","author":"Jayakrishnan","volume":"334","first-page":"1373","unstructured":null,"article-title":"Early-onset gastrointestinal cancers: a review.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1136/gutjnl-2020-321600","key":"jrv250035r6","year":"2020","issue":"9","author":"Arnold","volume":"69","first-page":"1564","unstructured":null,"article-title":"Global burden of oesophageal and gastric cancer by histology and subsite in 2018.","journal-title":"Gut","doi-asserted-by":"publisher"},{"DOI":"10.1016/S2214-109X(19)30488-7","key":"jrv250035r7","year":"2020","issue":"2","author":"de Martel","volume":"8","first-page":"e180","unstructured":null,"article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis.","journal-title":"Lancet Glob Health","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa001999","key":"jrv250035r8","year":"2001","issue":"11","author":"Uemura","volume":"345","first-page":"784","unstructured":null,"article-title":"Helicobacter pylori infection and the development of gastric cancer.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1053/j.gastro.2023.12.022","key":"jrv250035r9","year":"2024","issue":"4","author":"Chen","volume":"166","first-page":"605","unstructured":null,"article-title":"Global prevalence of Helicobacter pylori infection and incidence of gastric cancer between 1980 and 2022.","journal-title":"Gastroenterology","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.cgh.2022.07.042","key":"jrv250035r10","year":"2023","issue":"4","author":"Hirabayashi","volume":"21","first-page":"922","unstructured":null,"article-title":"Estimating the global burden of Epstein-Barr virus–associated gastric cancer: a systematic review and meta-analysis.","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"publisher"},{"DOI":"10.3390/cancers13153844","key":"jrv250035r11","year":"2021","issue":"15","author":"Vitelli-Storelli","volume":"13","first-page":"3844","unstructured":null,"article-title":"Family history and gastric cancer risk: a pooled investigation in the Stomach Cancer Pooling (STOP) project consortium.","journal-title":"Cancers (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.1097/CEJ.0000000000000290","key":"jrv250035r12","year":"2018","issue":"2","author":"Praud","volume":"27","first-page":"124","unstructured":null,"article-title":"Cigarette smoking and gastric cancer in the Stomach Cancer Pooling (STOP) project.","journal-title":"Eur J Cancer Prev","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.canep.2018.04.009","key":"jrv250035r13","year":"2018","issue":null,"author":"Ferro","volume":"54","first-page":"125","unstructured":null,"article-title":"Alcohol intake and gastric cancer: meta-analyses of published data versus individual participant data pooled analyses (STOP project).","journal-title":"Cancer Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.1097/CEJ.0000000000000874","key":"jrv250035r14","year":"2024","issue":"5","author":"Pelucchi","volume":"33","first-page":"433","unstructured":null,"article-title":"The global gastric cancer consortium: an update from the Stomach Cancer Pooling (STOP) project.","journal-title":"Eur J Cancer Prev","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10552-022-01565-y","key":"jrv250035r15","year":"2022","issue":"5","author":"Morais","volume":"33","first-page":"779","unstructured":null,"article-title":"Salt intake and gastric cancer: a pooled analysis within the Stomach Cancer Pooling (STOP) project.","journal-title":"Cancer Causes Control","doi-asserted-by":"publisher"},{"DOI":"10.3390/cancers14194905","key":"jrv250035r16","year":"2022","issue":"19","author":"Paragomi","volume":"14","first-page":"4905","unstructured":null,"article-title":"The association between peptic ulcer disease and gastric cancer: results from the Stomach Cancer Pooling (STOP) project consortium.","journal-title":"Cancers (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10552-004-3485-7","key":"jrv250035r17","year":"2005","issue":"3","author":"Lindblad","volume":"16","first-page":"285","unstructured":null,"article-title":"Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study.","journal-title":"Cancer Causes Control","doi-asserted-by":"publisher"},{"DOI":"10.1158/1055-9965.EPI-13-0042","key":"jrv250035r18","year":"2013","issue":"8","author":"Chen","volume":"22","first-page":"1395","unstructured":null,"article-title":"Body mass index and risk of gastric cancer: a meta-analysis of a population with more than ten million from 24 prospective studies.","journal-title":"Cancer Epidemiol Biomarkers Prev","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(14)71016-2","key":"jrv250035r19","year":"2015","issue":"2","author":"Oliveira","volume":"16","first-page":"e60","unstructured":null,"article-title":"Familial gastric cancer: genetic susceptibility, pathology, and implications for management.","journal-title":"Lancet Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaoncol.2014.168","key":"jrv250035r20","year":"2015","issue":"1","author":"Hansford","volume":"1","first-page":"23","unstructured":null,"article-title":"Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond.","journal-title":"JAMA Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2211807","key":"jrv250035r21","year":"2023","issue":"13","author":"Usui","volume":"388","first-page":"1181","unstructured":null,"article-title":"Helicobacter pylori, homologous-recombination genes, and gastric cancer.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.gie.2022.10.026","key":"jrv250035r22","year":"2023","issue":"3","author":"Singh","volume":"97","first-page":"407","unstructured":null,"article-title":"Occurrence of gastric cancer in patients with juvenile polyposis syndrome: a systematic review and meta-analysis.","journal-title":"Gastrointest Endosc","doi-asserted-by":"publisher"},{"DOI":"10.1038/ajg.2009.725","key":"jrv250035r23","year":"2010","issue":"6","author":"van Lier","volume":"105","first-page":"1258","unstructured":null,"article-title":"High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations.","journal-title":"Am J Gastroenterol","doi-asserted-by":"publisher"},{"DOI":"10.3390/cancers14235953","key":"jrv250035r24","year":"2022","issue":"23","author":"Buckley","volume":"14","first-page":"5953","unstructured":null,"article-title":"Gastric cancer risk and pathogenesis in BRCA1 and BRCA2 carriers.","journal-title":"Cancers (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.21.02112","key":"jrv250035r25","year":"2022","issue":"14","author":"Li","volume":"40","first-page":"1529","unstructured":null,"article-title":"Cancer risks associated With BRCA1 and BRCA2 pathogenic variants.","journal-title":"J Clin Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaoncol.2022.0476","key":"jrv250035r26","year":"2022","issue":"6","author":"Momozawa","volume":"8","first-page":"871","unstructured":null,"article-title":"Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants.","journal-title":"JAMA Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1708423","key":"jrv250035r27","year":"2018","issue":"12","author":"Choi","volume":"378","first-page":"1085","unstructured":null,"article-title":"Helicobacter pylori therapy for the prevention of metachronous gastric cancer.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1909666","key":"jrv250035r28","year":"2020","issue":"5","author":"Choi","volume":"382","first-page":"427","unstructured":null,"article-title":"Family history of gastric cancer and Helicobacter pylori treatment.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41591-024-03153-w","key":"jrv250035r29","year":"2024","issue":"11","author":"Pan","volume":"30","first-page":"3250","unstructured":null,"article-title":"Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial.","journal-title":"Nat Med","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2024.14887","key":"jrv250035r30","year":"2024","issue":"19","author":"Lee","volume":"332","first-page":"1642","unstructured":null,"article-title":"Screening for Helicobacter pylori to prevent gastric cancer: a pragmatic randomized clinical trial.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1136/gutjnl-2020-320839","key":"jrv250035r31","year":"2020","issue":"12","author":"Ford","volume":"69","first-page":"2113","unstructured":null,"article-title":"Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis.","journal-title":"Gut","doi-asserted-by":"publisher"},{"DOI":"10.1111/den.14063","key":"jrv250035r32","year":"2022","issue":"3","author":"Mabe","volume":"34","first-page":"412","unstructured":null,"article-title":"Endoscopic screening for gastric cancer in Japan: current status and future perspectives.","journal-title":"Dig Endosc","doi-asserted-by":"publisher"},{"DOI":"10.1053/j.gastro.2017.01.029","key":"jrv250035r33","year":"2017","issue":"6","author":"Jun","volume":"152","first-page":"1319","unstructured":null,"article-title":"Effectiveness of the Korean national cancer screening program in reducing gastric cancer mortality.","journal-title":"Gastroenterology","doi-asserted-by":"publisher"},{"DOI":"10.4143/crt.2025.264","key":"jrv250035r34","year":"2025","issue":"2","author":"Park","volume":"57","first-page":"312","unstructured":null,"article-title":"Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2022.","journal-title":"Cancer Res Treat","doi-asserted-by":"publisher"},{"DOI":"10.1111/cas.15545","key":"jrv250035r35","year":"2022","issue":"11","author":"Narii","volume":"113","first-page":"3922","unstructured":null,"article-title":"Effectiveness of endoscopic screening for gastric cancer: the Japan public health center-based prospective study.","journal-title":"Cancer Sci","doi-asserted-by":"publisher"},{"DOI":"10.1053/j.gastro.2024.11.001","key":"jrv250035r36","year":"2025","issue":"2","author":"Shah","volume":"168","first-page":"405","unstructured":null,"article-title":"AGA clinical practice update on screening and surveillance in individuals at increased risk for gastric cancer in the United States: expert review.","journal-title":"Gastroenterology","doi-asserted-by":"publisher"},{"DOI":"10.1111/apm.1965.64.1.31","key":"jrv250035r37","year":"1965","issue":null,"author":"Lauren","volume":"64","first-page":"31","unstructured":null,"article-title":"The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification.","journal-title":"Acta Pathol Microbiol Scand","doi-asserted-by":"publisher"},{"DOI":"10.1038/nm.3850","key":"jrv250035r38","year":"2015","issue":"5","author":"Cristescu","volume":"21","first-page":"449","unstructured":null,"article-title":"Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.","journal-title":"Nat Med","doi-asserted-by":"publisher"},{"DOI":"10.1038/nature13480","key":"jrv250035r39","year":"2014","issue":"7517","author":"Cancer Genome Atlas Research Network","volume":"513","first-page":"202","unstructured":null,"article-title":"Comprehensive molecular characterization of gastric adenocarcinoma.","journal-title":"Nature","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ccell.2018.03.010","key":"jrv250035r40","year":"2018","issue":"4","author":"Liu","volume":"33","first-page":"721","unstructured":null,"article-title":"Comparative molecular analysis of gastrointestinal adenocarcinomas.","journal-title":"Cancer Cell","doi-asserted-by":"publisher"},{"DOI":"10.1158/0008-5472.CAN-11-3893","key":"jrv250035r41","year":"2012","issue":"17","author":"Dulak","volume":"72","first-page":"4383","unstructured":null,"article-title":"Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis.","journal-title":"Cancer Res","doi-asserted-by":"publisher"},{"DOI":"10.1136/jitc-2021-004080","key":"jrv250035r42","year":"2022","issue":"3","author":"Bai","volume":"10","first-page":null,"unstructured":null,"article-title":"Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.","journal-title":"J Immunother Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.amjsurg.2017.10.030","key":"jrv250035r43","year":"2018","issue":"2","author":"Solsky","volume":"216","first-page":"286","unstructured":null,"article-title":"Gastric cancer diagnosis after presentation to the ED: the independent association of presenting location and outcomes.","journal-title":"Am J Surg","doi-asserted-by":"publisher"},{"DOI":"10.1097/00000658-199321850-00002","key":"jrv250035r44","year":"1993","issue":"5","author":"Wanebo","volume":"218","first-page":"583","unstructured":null,"article-title":"Cancer of the stomach: a patient care study by the American College of Surgeons.","journal-title":"Ann Surg","doi-asserted-by":"publisher"},{"DOI":"10.1097/MEG.0000000000001251","key":"jrv250035r45","year":"2018","issue":"12","author":"Tang","volume":"30","first-page":"1497","unstructured":null,"article-title":"Iron deficiency anemia in gastric cancer: a Canadian retrospective review.","journal-title":"Eur J Gastroenterol Hepatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.gie.2015.04.003","key":"jrv250035r46","year":"2015","issue":"2","author":"Shaukat","volume":"82","first-page":"227","unstructured":null,"article-title":"The role of endoscopy in dyspepsia.","journal-title":"Gastrointest Endosc","doi-asserted-by":"publisher"},{"DOI":"10.1053/j.gastro.2005.09.019","key":"jrv250035r47","year":"2005","issue":"5","author":"Talley","volume":"129","first-page":"1753","unstructured":null,"article-title":"American Gastroenterological Association medical position statement: evaluation of dyspepsia.","journal-title":"Gastroenterology","doi-asserted-by":"publisher"},{"DOI":"10.1053/j.gastro.2005.09.020","key":"jrv250035r48","year":"2005","issue":"5","author":"Talley","volume":"129","first-page":"1756","unstructured":null,"article-title":"American gastroenterological association technical review on the evaluation of dyspepsia.","journal-title":"Gastroenterology","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.amsu.2022.103411","key":"jrv250035r49","year":"2022","issue":null,"author":"Mranda","volume":"75","first-page":null,"unstructured":null,"article-title":"Revisiting the 8th AJCC system for gastric cancer: a review on validations, nomograms, lymph nodes impact, and proposed modifications.","journal-title":"Ann Med Surg (Lond)","doi-asserted-by":"publisher"},{"DOI":"10.1080/17474124.2018.1413348","key":"jrv250035r50","year":"2018","issue":"5","author":"Abdel-Rahman","volume":"12","first-page":"525","unstructured":null,"article-title":"Validation of the 8th AJCC staging system for gastric cancer in a population-based setting.","journal-title":"Expert Rev Gastroenterol Hepatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(18)32557-1","key":"jrv250035r51","year":"2019","issue":"10184","author":"Al-Batran","volume":"393","first-page":"1948","unstructured":null,"article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.amjsurg.2022.01.024","key":"jrv250035r52","year":"2022","issue":null,"author":"Sirody","volume":"224","first-page":"445","unstructured":null,"article-title":"Patterns of gastric cancer metastasis in the United States.","journal-title":"Am J Surg","doi-asserted-by":"publisher"},{"DOI":"10.18632/oncotarget.10740","key":"jrv250035r53","year":"2016","issue":"32","author":"Riihimäki","volume":"7","first-page":"52307","unstructured":null,"article-title":"Metastatic spread in patients with gastric cancer.","journal-title":"Oncotarget","doi-asserted-by":"publisher"},{"DOI":"10.6004/jnccn.2022.0008","key":"jrv250035r54","year":"2022","issue":"2","author":"Ajani","volume":"20","first-page":"167","unstructured":null,"article-title":"Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology.","journal-title":"J Natl Compr Canc Netw","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.annonc.2022.07.004","key":"jrv250035r55","year":"2022","issue":"10","author":"Lordick","volume":"33","first-page":"1005","unstructured":null,"article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up.","journal-title":"Ann Oncol","doi-asserted-by":"publisher"},{"DOI":"10.3390/diagnostics11010134","key":"jrv250035r56","year":"2021","issue":"1","author":"Ungureanu","volume":"11","first-page":"134","unstructured":null,"article-title":"Endoscopic ultrasound vs computed tomography for gastric cancer staging: a network meta-analysis.","journal-title":"Diagnostics (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10120-011-0017-5","key":"jrv250035r57","year":"2011","issue":"1","author":"Shimada","volume":"14","first-page":"13","unstructured":null,"article-title":"Japanese Gastric Cancer Association task force for research promotion: clinical utility of 18F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. a systematic review of the literature.","journal-title":"Gastric Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1002/cncr.27550","key":"jrv250035r58","year":"2012","issue":"22","author":"Smyth","volume":"118","first-page":"5481","unstructured":null,"article-title":"A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.","journal-title":"Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1002/cncr.21074","key":"jrv250035r59","year":"2005","issue":"11","author":"Chen","volume":"103","first-page":"2383","unstructured":null,"article-title":"Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography.","journal-title":"Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamasurg.2021.5340","key":"jrv250035r60","year":"2021","issue":"12","author":"Gertsen","volume":"156","first-page":null,"unstructured":null,"article-title":"18F-fludeoxyglucose-positron emission tomography/computed tomography and laparoscopy for staging of locally advanced gastric cancer: a multicenter prospective Dutch cohort study (PLASTIC).","journal-title":"JAMA Surg","doi-asserted-by":"publisher"},{"DOI":"10.1097/SLE.0000000000000451","key":"jrv250035r61","year":"2017","issue":"5","author":"Leeman","volume":"27","first-page":"369","unstructured":null,"article-title":"Multidetector computed tomography versus staging laparoscopy for the detection of peritoneal metastases in esophagogastric junctional and gastric cancer.","journal-title":"Surg Laparosc Endosc Percutan Tech","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.gie.2023.03.015","key":"jrv250035r62","year":"2023","issue":"3","author":"Forbes","volume":"98","first-page":"271","unstructured":null,"article-title":"American Society for Gastrointestinal Endoscopy guideline on endoscopic submucosal dissection for the management of early esophageal and gastric cancers: summary and recommendations.","journal-title":"Gastrointest Endosc","doi-asserted-by":"publisher"},{"DOI":"10.1245/s10434-019-07417-5","key":"jrv250035r63","year":"2019","issue":"9","author":"Mogal","volume":"26","first-page":"2912","unstructured":null,"article-title":"In patients with localized and resectable gastric cancer, what is the optimal extent of lymph node dissection-D1 versus D2 versus D3?","journal-title":"Ann Surg Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(11)61873-4","key":"jrv250035r64","year":"2012","issue":"9813","author":"Bang","volume":"379","first-page":"315","unstructured":null,"article-title":"Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2503701","key":"jrv250035r65","year":"2025","issue":"3","author":"Janjigian","volume":"393","first-page":"217","unstructured":null,"article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2405195","key":"jrv250035r66","year":"2024","issue":"19","author":"Leong","volume":"391","first-page":"1810","unstructured":null,"article-title":"Preoperative chemoradiotherapy for resectable gastric cancer.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1112088","key":"jrv250035r67","year":"2012","issue":"22","author":"van Hagen","volume":"366","first-page":"2074","unstructured":null,"article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1245/s10434-021-11050-6","key":"jrv250035r68","year":"2022","issue":"4","author":"Nie","volume":"29","first-page":"2324","unstructured":null,"article-title":"Adjuvant chemotherapy for gastric cancer patients with mismatch repair deficiency or microsatellite instability: systematic review and meta-analysis.","journal-title":"Ann Surg Oncol","doi-asserted-by":"publisher"},{"DOI":"10.4143/crt.2020.313","key":"jrv250035r69","year":"2020","issue":"4","author":"Kim","volume":"52","first-page":"1178","unstructured":null,"article-title":"Adjuvant chemotherapy in microsatellite instability-high gastric cancer.","journal-title":"Cancer Res Treat","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.19.01124","key":"jrv250035r70","year":"2019","issue":"35","author":"Pietrantonio","volume":"37","first-page":"3392","unstructured":null,"article-title":"Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer.","journal-title":"J Clin Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clinre.2021.101691","key":"jrv250035r71","year":"2021","issue":"4","author":"Tran-Minh","volume":"45","first-page":null,"unstructured":null,"article-title":"Prevalence and prognosis of microsatellite instability in oesogastric adenocarcinoma, NORDICAP 16-01.","journal-title":"Clin Res Hepatol Gastroenterol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaoncol.2021.0275","key":"jrv250035r72","year":"2021","issue":"6","author":"Chao","volume":"7","first-page":"895","unstructured":null,"article-title":"Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials.","journal-title":"JAMA Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.22.00686","key":"jrv250035r73","year":"2023","issue":"2","author":"André","volume":"41","first-page":"255","unstructured":null,"article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study.","journal-title":"J Clin Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaoncol.2016.6762","key":"jrv250035r74","year":"2017","issue":"9","author":"Smyth","volume":"3","first-page":"1197","unstructured":null,"article-title":"Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial.","journal-title":"JAMA Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1093/annonc/mdn717","key":"jrv250035r75","year":"2009","issue":"4","author":"Kang","volume":"20","first-page":"666","unstructured":null,"article-title":"Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.","journal-title":"Ann Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(10)61121-X","key":"jrv250035r76","year":"2010","issue":"9742","author":"Bang","volume":"376","first-page":"687","unstructured":null,"article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(23)02033-0","key":"jrv250035r77","year":"2023","issue":"10418","author":"Janjigian","volume":"402","first-page":"2197","unstructured":null,"article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMc2408121","key":"jrv250035r78","year":"2024","issue":"14","author":"Janjigian","volume":"391","first-page":"1360","unstructured":null,"article-title":"Pembrolizumab in HER2–positive gastric cancer.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(21)00797-2","key":"jrv250035r79","year":"2021","issue":"10294","author":"Janjigian","volume":"398","first-page":"27","unstructured":null,"article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.23.01601","key":"jrv250035r80","year":"2024","issue":"17","author":"Janjigian","volume":"42","first-page":"2012","unstructured":null,"article-title":"First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 Trial.","journal-title":"J Clin Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(23)00515-6","key":"jrv250035r81","year":"2023","issue":"11","author":"Rha","volume":"24","first-page":"1181","unstructured":null,"article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.","journal-title":"Lancet Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(23)00620-7","key":"jrv250035r82","year":"2023","issue":"10389","author":"Shitara","volume":"401","first-page":"1655","unstructured":null,"article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMc2409512","key":"jrv250035r83","year":"2024","issue":"12","author":"Shitara","volume":"391","first-page":"1159","unstructured":null,"article-title":"Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41591-023-02465-7","key":"jrv250035r84","year":"2023","issue":"8","author":"Shah","volume":"29","first-page":"2133","unstructured":null,"article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.","journal-title":"Nat Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(14)70420-6","key":"jrv250035r85","year":"2014","issue":"11","author":"Wilke","volume":"15","first-page":"1224","unstructured":null,"article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.","journal-title":"Lancet Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2004413","key":"jrv250035r86","year":"2020","issue":"25","author":"Shitara","volume":"382","first-page":"2419","unstructured":null,"article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(18)30739-3","key":"jrv250035r87","year":"2018","issue":"11","author":"Shitara","volume":"19","first-page":"1437","unstructured":null,"article-title":"Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.","journal-title":"Lancet Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10120-014-0402-y","key":"jrv250035r88","year":"2015","issue":"3","author":"Van Cutsem","volume":"18","first-page":"476","unstructured":null,"article-title":"HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.","journal-title":"Gastric Cancer","doi-asserted-by":"publisher"},{"DOI":"10.3748/wjg.v22.i19.4619","key":"jrv250035r89","year":"2016","issue":"19","author":"Abrahao-Machado","volume":"22","first-page":"4619","unstructured":null,"article-title":"HER2 testing in gastric cancer: an update.","journal-title":"World J Gastroenterol","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj-2023-078876","key":"jrv250035r90","year":"2024","issue":null,"author":"Qiu","volume":"385","first-page":null,"unstructured":null,"article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":"10.1093/annonc/mdv625","key":"jrv250035r91","year":"2016","issue":"4","author":"Al-Batran","volume":"27","first-page":"673","unstructured":null,"article-title":"Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma.","journal-title":"Ann Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ejca.2022.01.015","key":"jrv250035r92","year":"2022","issue":null,"author":"Lorenzen","volume":"165","first-page":"48","unstructured":null,"article-title":"FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel—results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO.","journal-title":"Eur J Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1634/theoncologist.2018-0602","key":"jrv250035r93","year":"2019","issue":"4","author":"Klempner","volume":"24","first-page":"475","unstructured":null,"article-title":"Initial report of second-line FOLFIRI in combination with ramucirumab in advanced gastroesophageal adenocarcinomas: a multi-institutional retrospective analysis.","journal-title":"Oncologist","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(13)70549-7","key":"jrv250035r94","year":"2014","issue":"1","author":"Ford","volume":"15","first-page":"78","unstructured":null,"article-title":"Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.","journal-title":"Lancet Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(13)61719-5","key":"jrv250035r95","year":"2014","issue":"9911","author":"Fuchs","volume":"383","first-page":"31","unstructured":null,"article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00280-012-2027-3","key":"jrv250035r96","year":"2013","issue":"2","author":"Sym","volume":"71","first-page":"481","unstructured":null,"article-title":"A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy.","journal-title":"Cancer Chemother Pharmacol","doi-asserted-by":"publisher"},{"DOI":"10.21037/jgo-23-1000","key":"jrv250035r97","year":"2024","issue":"1","author":"Jiang","volume":"15","first-page":"96","unstructured":null,"article-title":"Lack of clinical benefit from preoperative short-term parenteral nutrition on the clinical prognosis of patients treated with radical gastrectomy for gastric cancer: a two-center retrospective study based on propensity score matching analysis.","journal-title":"J Gastrointest Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1136/spcare-2024-005183","key":"jrv250035r98","year":"2025","issue":null,"author":"He","volume":null,"first-page":null,"unstructured":null,"article-title":"Early oral feeding post gastrectomy in gastric cancer: quasi-experimental study.","journal-title":"BMJ Support Palliat Care","doi-asserted-by":"publisher"},{"DOI":"10.1002/jso.23983","key":"jrv250035r99","year":"2015","issue":"2","author":"Dann","volume":"112","first-page":"195","unstructured":null,"article-title":"An assessment of feeding jejunostomy tube placement at the time of resection for gastric adenocarcinoma: a seven-institution analysis of 837 patients from the US gastric cancer collaborative.","journal-title":"J Surg Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(80)91406-3","key":"jrv250035r100","year":"1980","issue":"8175","author":"Tovey","volume":"1","first-page":"956","unstructured":null,"article-title":"Anaemia after partial gastrectomy: a neglected curable condition.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1007/s002689900379","key":"jrv250035r101","year":"1998","issue":"3","author":"Bae","volume":"22","first-page":"254","unstructured":null,"article-title":"Nutritional status of gastric cancer patients after total gastrectomy.","journal-title":"World J Surg","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10120-017-0777-7","key":"jrv250035r102","year":"2018","issue":"4","author":"Yoo","volume":"21","first-page":"720","unstructured":null,"article-title":"Risk of osteoporosis after gastrectomy in long-term gastric cancer survivors.","journal-title":"Gastric Cancer","doi-asserted-by":"publisher"},{"DOI":"10.3390/nu14132712","key":"jrv250035r103","year":"2022","issue":"13","author":"Muszynski","volume":"14","first-page":"2712","unstructured":null,"article-title":"Vitamin D—the nutritional status of post-gastrectomy gastric cancer patients—systematic review.","journal-title":"Nutrients","doi-asserted-by":"publisher"},{"DOI":"10.1007/s12029-023-01001-7","key":"jrv250035r104","year":"2024","issue":"2","author":"Cobani","volume":"55","first-page":"519","unstructured":null,"article-title":"Gastric cancer survivorship: multidisciplinary management, best practices and opportunities.","journal-title":"J Gastrointest Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1007/s101200200014","key":"jrv250035r105","year":"2002","issue":"2","author":"Kubo","volume":"5","first-page":"83","unstructured":null,"article-title":"Endoscopic evaluation of the remnant stomach after gastrectomy: proposal for a new classification.","journal-title":"Gastric Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.20.01254","key":"jrv250035r106","year":"2021","issue":"7","author":"Lu","volume":"39","first-page":"748","unstructured":null,"article-title":"Early interdisciplinary supportive care in patients with previously untreated metastatic esophagogastric cancer: a phase III randomized controlled trial.","journal-title":"J Clin Oncol","doi-asserted-by":"publisher"}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA"],"reference-count":106,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,7]]},"references-count":106,"short-container-title":["JAMA"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jama.2025.20034","is_oa":false,"title":"Gastric Cancer","updated":"2026-01-10T04:46:20+00:00","published_date":"2026-01-07","best_oa_location":null}},"created_at":"2026-01-18T22:40:12.285Z","updated_at":"2026-01-19T09:31:36.873Z","tags":[{"paper_doi":"10.1001/jama.2025.20034","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"category","value":"Medicine, General & Internal","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"condition","value":"Gastric Cancer","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"generic","value":"durvalumab","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"generic","value":"nivolumab","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"generic","value":"pembrolizumab","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"generic","value":"trastuzumab","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"generic","value":"zolbetuximab","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"modality","value":"CLDN18.2 Antibody","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"modality","value":"Cytotoxic Chemotherapy","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"modality","value":"HER2-Targeted Therapy","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"modality","value":"Immune Checkpoint Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"warning","value":"Specific trial methods and eligibility (e.g., PD-L1 thresholds, CLDN18.2 assay criteria) are not detailed.","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"warning","value":"The perioperative regimen including durvalumab is cited without study identifiers or dosing details.","value_numeric":null},{"paper_doi":"10.1001/jama.2025.20034","tag_type":"warning","value":"This is a narrative review summarizing multiple studies, not a single trial.","value_numeric":null}],"summaries":{"what_studied":"Narrative review of gastric cancer epidemiology, presentation, screening, diagnosis, and treatment, with quantified outcomes for surgery, chemoimmunotherapy, and targeted therapy. It reports incidence (968,350 new cases and 659,853 deaths worldwide in 2022; 30,300 cases and 10,780 deaths in the US in 2025) and biomarker-driven management.","key_result":"At diagnosis, about 13% have localized, 15%–25% locally advanced, and 35%–65% metastatic disease; resection of localized cancer yields a 5-year relative survival of 75%, while fewer than 10% with metastatic disease live 5 years. In PD-L1–expressing tumors, adding nivolumab or pembrolizumab to chemotherapy adds ~3 months of survival; adding trastuzumab (ERBB2) or zolbetuximab (CLDN18.2) adds 3–4 months; early supportive care adds ~3 months; routine endoscopic screening from age 40 in high-incidence countries is associated with improved survival.","practice_takeaway":"Test for PD-L1, ERBB2, and CLDN18.2 in unresectable or metastatic gastric cancer to select immunotherapy or targeted therapy that can extend survival by several months. Use gastrectomy for localized disease and perioperative 5-fluorouracil/oxaliplatin/docetaxel plus durvalumab for more advanced resectable disease; initiate early supportive care, and in high-incidence regions, employ routine endoscopic screening from age 40."}},{"doi":"10.1136/gutjnl-2025-336966","pmid":"41482458","title":"Streptococcus anginosus\n -derived methionine promotes gastric cancer progression","journal_title":"Gut","journal_issn":"0017-5749","published_at":"2026-01-03T00:00:00.000Z","url":"https://doi.org/10.1136/gutjnl-2025-336966","source_score":85,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-01-06","doi":"10.1136/gutjnl-2025-336966","days":"30","issn":"0017-5749","rank":"8","field":"Clinical Medicine","score":"85","category":"Gastroenterology & Hepatology","categories":["Gastroenterology & Hepatology"],"_categories":["Gastroenterology & Hepatology"]},"pubmed":{"doi":"10.1136/gutjnl-2025-336966","title":"","journal":"Gut","methods":"","results":"We verified ","abstract":"To investigate the promotional effect of \nWe used the functional profiles of shotgun metagenomic sequencing from stools to detect bioactive molecules relevant to \nWe verified \nOur results elucidate the role of ","keywords":["GASTRIC CANCER","METAGENOMICS","MICROBIOME"],"pubmed_id":"41482458","conclusions":"Our results elucidate the role of ","publication_date":"2026-01-03T00:00:00"},"crossref":{"DOI":"10.1136/gutjnl-2025-336966","URL":"https://doi.org/10.1136/gutjnl-2025-336966","ISSN":["0017-5749","1468-3288"],"link":[{"URL":"https://syndication.highwire.org/content/doi/10.1136/gutjnl-2025-336966","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"gutjnl-2025-336966","type":"journal-article","issue":null,"score":1,"title":["Streptococcus anginosus\n -derived methionine promotes gastric cancer progression"],"author":[{"given":"Cheng-Bei","family":"Zhou","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology; Shanghai Institute of Digestive Disease; NHC Key Laboratory of Digestive Diseases; State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China"}]},{"given":"Li-Cong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology; Shanghai Institute of Digestive Disease; NHC Key Laboratory of Digestive Diseases; State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China"}]},{"given":"Youwen","family":"Qin","sequence":"additional","affiliation":[{"name":"BGI Genomics, Shenzhen, China"},{"name":"State Key Laboratory of Genome and Multi-omics Technologies, BGI Research, Shenzhen, China"}]},{"given":"Jingchen","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}]},{"given":"Wenxi","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Genome and Multi-omics Technologies, BGI Research, Shenzhen, China"}]},{"given":"Qianhui","family":"Feng","sequence":"additional","affiliation":[{"name":"BGI Genomics, Shenzhen, China"},{"name":"School of Biological Sciences & Medical Engineering, Southeast University, Nanjing, China"}]},{"given":"Xin","family":"Tong","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Genome and Multi-omics Technologies, BGI Research, Shenzhen, China"}]},{"given":"Resalaiti","family":"Abuduaini","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology; Shanghai Institute of Digestive Disease; NHC Key Laboratory of Digestive Diseases; State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China"}]},{"given":"Shi-Yuan","family":"Lu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology; Shanghai Institute of Digestive Disease; NHC Key Laboratory of Digestive Diseases; State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China"},{"name":"Department of Gastroenterology, Secondary Affiliated Hospital of Zhejiang University, Hangzhou, China"}]},{"given":"Huang","family":"Tang","sequence":"additional","affiliation":[{"name":"Laboratory of Bacterial Pathogenesis, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}]},{"given":"Ya-Xuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology; Shanghai Institute of Digestive Disease; NHC Key Laboratory of Digestive Diseases; State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China"}]},{"given":"Yun","family":"Cui","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology; Shanghai Institute of Digestive Disease; NHC Key Laboratory of Digestive Diseases; State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China"}]},{"given":"Liang","family":"Xiao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Genome and Multi-omics Technologies, BGI Research, Shenzhen, China"}]},{"given":"Lin-Hong","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology; Shanghai Institute of Digestive Disease; NHC Key Laboratory of Digestive Diseases; State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China"}]},{"given":"Le-Kai","family":"Ni","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology; Shanghai Institute of Digestive Disease; NHC Key Laboratory of Digestive Diseases; State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China"}]},{"given":"Kui","family":"Wu","sequence":"additional","affiliation":[{"name":"BGI Genomics, Shenzhen, China"}]},{"given":"Huanzi","family":"Zhong","sequence":"additional","affiliation":[{"name":"BGI Genomics, Shenzhen, China"}]},{"given":"Yi-Chao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology; Shanghai Institute of Digestive Disease; NHC Key Laboratory of Digestive Diseases; State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China"}]},{"given":"Yuanqiang","family":"Zou","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Genome and Multi-omics Technologies, BGI Research, Shenzhen, China"}]},{"given":"Xiao-Xu","family":"Leng","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology; Shanghai Institute of Digestive Disease; NHC Key Laboratory of Digestive Diseases; State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China"}]},{"given":"Ming","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China"}]},{"given":"Wen-Yi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China"}]},{"given":"Chao-Jie","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China"}]},{"given":"Jia-Qi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"}]},{"given":"Cheng","family":"Hu","sequence":"additional","affiliation":[{"name":"Experiment Center for Science and Technology, Shanghai University of Traditional Chinese Medicine, Shanghai, China"}]},{"given":"Ying-Xuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology; Shanghai Institute of Digestive Disease; NHC Key Laboratory of Digestive Diseases; State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China"}]},{"given":"Yu-Feng","family":"Yao","sequence":"additional","affiliation":[{"name":"Laboratory of Bacterial Pathogenesis, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}]},{"given":"Shida","family":"Zhu","sequence":"additional","affiliation":[{"name":"BGI Genomics, Shenzhen, China"}]},{"given":"Jing-Yuan","family":"Fang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology; Shanghai Institute of Digestive Disease; NHC Key Laboratory of Digestive Diseases; State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China"}]}],"funder":[{"id":[{"id":"10.13039/100020732","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100020732","name":"Innovative Research Team of High-level Local University in Shanghai","award":["SHSMU-ZDCX2021030"],"award-info":[{"award-number":["SHSMU-ZDCX2021030"]}],"doi-asserted-by":"publisher"},{"name":"Chenguang Program of Shanghai Education Development Foundation and Shanghai Municipal Education Commission","award":["22CGA17"],"award-info":[{"award-number":["22CGA17"]}]},{"id":[{"id":"10.13039/501100002858","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100002858","name":"China Postdoctoral Science Foundation","award":["2022M712124"],"award-info":[{"award-number":["2022M712124"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/501100001809","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100001809","name":"National Natural Science Foundation of China","award":["8220110843"],"award-info":[{"award-number":["8220110843"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/501100001809","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100001809","name":"National Natural Science Foundation of China","award":["82203224"],"award-info":[{"award-number":["82203224"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/501100001809","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100001809","name":"National Natural Science Foundation of China","award":["82250005"],"award-info":[{"award-number":["82250005"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/501100001809","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100001809","name":"National Natural Science Foundation of China","award":["82330086"],"award-info":[{"award-number":["82330086"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/501100001809","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100001809","name":"National Natural Science Foundation of China","award":["82570645"],"award-info":[{"award-number":["82570645"]}],"doi-asserted-by":"publisher"},{"name":"Clinical Research Plan of SHDC","award":["SHDC2020CR1034B"],"award-info":[{"award-number":["SHDC2020CR1034B"]}]},{"name":"Guangdong Genomics Data Center","award":["2021B1212100001"],"award-info":[{"award-number":["2021B1212100001"]}]},{"id":[{"id":"10.13039/501100012166","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100012166","name":"National Key Research and Development Program of China","award":["2020YFA0509200"],"award-info":[{"award-number":["2020YFA0509200"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/501100012166","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100012166","name":"National Key Research and Development Program of China","award":["2025ZD0551704"],"award-info":[{"award-number":["2025ZD0551704"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/501100018625","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100018625","name":"Science and Technology Innovation Plan Of Shanghai Science and Technology Commission","award":["20JC1410100"],"award-info":[{"award-number":["20JC1410100"]}],"doi-asserted-by":"publisher"},{"name":"Shanghai Municipal Health Commission, Collaborative Innovation Cluster Project","award":["2019CXJQ02"],"award-info":[{"award-number":["2019CXJQ02"]}]},{"id":[{"id":"10.13039/501100013105","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100013105","name":"Shanghai Rising-Star Program","award":["24QA2705000"],"award-info":[{"award-number":["24QA2705000"]}],"doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2026,1,2]]},"member":"239","prefix":"10.1136","source":"Crossref","volume":null,"created":{"date-time":"2026-01-02T18:20:15Z","timestamp":1767378015000,"date-parts":[[2026,1,2]]},"indexed":{"date-time":"2026-01-02T18:25:52Z","timestamp":1767378352216,"date-parts":[[2026,1,2]]},"subject":[],"abstract":"$34","accepted":{"date-parts":[[2025,12,12]]},"language":"en","relation":{},"resource":{"primary":{"URL":"https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2025-336966"}},"subtitle":[],"deposited":{"date-time":"2026-01-02T18:20:20Z","timestamp":1767378020000,"date-parts":[[2026,1,2]]},"issn-type":[{"type":"print","value":"0017-5749"},{"type":"electronic","value":"1468-3288"}],"published":{"date-parts":[[2026,1,2]]},"publisher":"BMJ","reference":[{"DOI":"10.3322/CAAC.21834","key":"2026010210200889000_gutjnl-2025-336966v1.1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3322/caac.21660","key":"2026010210200889000_gutjnl-2025-336966v1.2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S2468-2667(23)00211-6","key":"2026010210200889000_gutjnl-2025-336966v1.3","year":"2023","issue":null,"author":"Qi","volume":"8","first-page":"e943","unstructured":null,"article-title":"National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data","journal-title":"Lancet Public Health","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2022.02.015","key":"2026010210200889000_gutjnl-2025-336966v1.4","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa001999","key":"2026010210200889000_gutjnl-2025-336966v1.5","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1128/CMR.00011-10","key":"2026010210200889000_gutjnl-2025-336966v1.6","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1053/j.gastro.2010.09.048","key":"2026010210200889000_gutjnl-2025-336966v1.7","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/hel.12145","key":"2026010210200889000_gutjnl-2025-336966v1.8","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3389/fcimb.2017.00302","key":"2026010210200889000_gutjnl-2025-336966v1.9","year":"2017","issue":null,"author":"Yu","volume":"7","first-page":null,"unstructured":null,"article-title":"Molecular Characterization of the Human Stomach Microbiota in Gastric Cancer Patients","journal-title":"Front Cell Infect Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(84)91816-6","key":"2026010210200889000_gutjnl-2025-336966v1.10","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1099/00207713-41-1-1","key":"2026010210200889000_gutjnl-2025-336966v1.11","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.cell.2024.01.004","key":"2026010210200889000_gutjnl-2025-336966v1.12","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ccell.2021.08.006","key":"2026010210200889000_gutjnl-2025-336966v1.13","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/1040841X.2018.1425671","key":"2026010210200889000_gutjnl-2025-336966v1.14","year":"2018","issue":null,"author":"Zhou","volume":"44","first-page":"436","unstructured":null,"article-title":"The regulation of host cellular and gut microbial metabolism in the development and prevention of colorectal cancer","journal-title":"Crit Rev Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cell.2011.02.013","key":"2026010210200889000_gutjnl-2025-336966v1.15","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1099/mic.0.077826-0","key":"2026010210200889000_gutjnl-2025-336966v1.16","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0378-1097(03)00215-5","key":"2026010210200889000_gutjnl-2025-336966v1.17","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1099/00221287-148-12-3961","key":"2026010210200889000_gutjnl-2025-336966v1.18","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1099/jmm.0.2008/001677-0","key":"2026010210200889000_gutjnl-2025-336966v1.19","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41568-019-0187-8","key":"2026010210200889000_gutjnl-2025-336966v1.20","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41591-019-0423-5","key":"2026010210200889000_gutjnl-2025-336966v1.21","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s42255-023-00854-3","key":"2026010210200889000_gutjnl-2025-336966v1.22","year":"2023","issue":null,"author":"Ji","volume":"5","first-page":"1526","unstructured":null,"article-title":"Methionine restriction-induced sulfur deficiency impairs antitumour immunity partially through gut microbiota","journal-title":"Nat Metab","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026010210200889000_gutjnl-2025-336966v1.23","year":"2022","issue":null,"author":"Sedillo","volume":"12","first-page":"2249","unstructured":null,"article-title":"Targeting the methionine addiction of cancer","journal-title":"Am J Cancer Res","doi-asserted-by":null},{"DOI":"10.1016/S0305-7372(03)00118-X","key":"2026010210200889000_gutjnl-2025-336966v1.24","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41586-024-07182-w","key":"2026010210200889000_gutjnl-2025-336966v1.25","year":"2024","issue":null,"author":"Zepeda-Rivera","volume":"628","first-page":"424","unstructured":null,"article-title":"A distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche","journal-title":"Nature New Biol","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41467-024-47523-x","key":"2026010210200889000_gutjnl-2025-336966v1.26","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.7554/eLife.65088","key":"2026010210200889000_gutjnl-2025-336966v1.27","year":"2021","issue":null,"author":"Beghini","volume":"10","first-page":null,"unstructured":null,"article-title":"Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3","journal-title":"Elife","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41587-020-00797-0","key":"2026010210200889000_gutjnl-2025-336966v1.28","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1158/0008-5472.CAN-06-4025","key":"2026010210200889000_gutjnl-2025-336966v1.29","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/nar/gkz862","key":"2026010210200889000_gutjnl-2025-336966v1.30","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/biom10040568","key":"2026010210200889000_gutjnl-2025-336966v1.31","year":"2020","issue":null,"author":"Kaiser","volume":"10","first-page":null,"unstructured":null,"article-title":"Methionine Dependence of Cancer","journal-title":"Biomolecules","doi-asserted-by":"crossref"},{"DOI":"10.1128/JB.00703-07","key":"2026010210200889000_gutjnl-2025-336966v1.32","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/biom14020161","key":"2026010210200889000_gutjnl-2025-336966v1.33","year":"2024","issue":null,"author":"Zou","volume":"14","first-page":null,"unstructured":null,"article-title":"The Role of Methionine Restriction in Gastric Cancer: A Summary of Mechanisms and a Discussion on Tumor Heterogeneity","journal-title":"Biomolecules","doi-asserted-by":"crossref"},{"DOI":"10.1038/s43018-024-00739-8","key":"2026010210200889000_gutjnl-2025-336966v1.34","year":"2024","issue":null,"author":"Lee","volume":"5","first-page":"707","unstructured":null,"article-title":"Cycling back to folate metabolism in cancer","journal-title":"Nat Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41467-024-46043-y","key":"2026010210200889000_gutjnl-2025-336966v1.35","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.acthis.2012.03.006","key":"2026010210200889000_gutjnl-2025-336966v1.36","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"2026010210200889000_gutjnl-2025-336966v1.37","year":"1998","issue":null,"author":"Cai","volume":"58","first-page":"1444","unstructured":null,"article-title":"Differential expression of methionine adenosyltransferase genes influences the rate of growth of human hepatocellular carcinoma cells","journal-title":"Cancer Res","doi-asserted-by":null},{"DOI":"10.1053/j.gastro.2007.03.114","key":"2026010210200889000_gutjnl-2025-336966v1.38","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/cr.2008.314","key":"2026010210200889000_gutjnl-2025-336966v1.39","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41392-021-00710-4","key":"2026010210200889000_gutjnl-2025-336966v1.40","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1872-034X.2007.00041.x","key":"2026010210200889000_gutjnl-2025-336966v1.41","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/1756-9966-27-72","key":"2026010210200889000_gutjnl-2025-336966v1.42","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1021/acs.jmedchem.2c00395","key":"2026010210200889000_gutjnl-2025-336966v1.43","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/metabo11020083","key":"2026010210200889000_gutjnl-2025-336966v1.44","year":"2021","issue":null,"author":"Lauinger","volume":"11","first-page":null,"unstructured":null,"article-title":"Sensing and Signaling of Methionine Metabolism","journal-title":"Metabolites","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41587-020-0501-8","key":"2026010210200889000_gutjnl-2025-336966v1.45","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41467-023-37396-x","key":"2026010210200889000_gutjnl-2025-336966v1.46","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41587-023-01688-w","key":"2026010210200889000_gutjnl-2025-336966v1.47","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.biotechadv.2004.08.005","key":"2026010210200889000_gutjnl-2025-336966v1.48","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1158/2159-8290.CD-21-1059","key":"2026010210200889000_gutjnl-2025-336966v1.49","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.celrep.2018.07.089","key":"2026010210200889000_gutjnl-2025-336966v1.50","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.cell.2013.02.035","key":"2026010210200889000_gutjnl-2025-336966v1.51","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41586-019-1437-3","key":"2026010210200889000_gutjnl-2025-336966v1.52","year":"2019","issue":null,"author":"Gao","volume":"572","first-page":"397","unstructured":null,"article-title":"Dietary methionine influences therapy in mouse cancer models and alters human metabolism","journal-title":"Nature New Biol","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41419-021-04396-y","key":"2026010210200889000_gutjnl-2025-336966v1.53","year":"2021","issue":null,"author":"Dai","volume":"12","first-page":null,"unstructured":null,"article-title":"Interactions between gastric microbiota and metabolites in gastric cancer","journal-title":"Cell Death Dis","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026010210200889000_gutjnl-2025-336966v1.54","year":"1988","issue":null,"author":"Judde","volume":"48","first-page":"6775","unstructured":null,"article-title":"Patterns of methionine auxotrophy in normal and neoplastic cells: the methionine independence of lymphocyte mitogenesis and low frequency of the methionine-dependent phenotype in human tumors","journal-title":"Cancer Res","doi-asserted-by":null},{"DOI":"10.1080/15384101.2020.1814044","key":"2026010210200889000_gutjnl-2025-336966v1.55","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.cell.2013.06.041","key":"2026010210200889000_gutjnl-2025-336966v1.56","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.freeradbiomed.2022.02.015","key":"2026010210200889000_gutjnl-2025-336966v1.57","year":"2022","issue":null,"author":"Ma","volume":"181","first-page":"288","unstructured":null,"article-title":"Activation of MAT2A-ACSL3 pathway protects cells from ferroptosis in gastric cancer","journal-title":"Free Radic Biol Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ijbiomac.2018.09.051","key":"2026010210200889000_gutjnl-2025-336966v1.58","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.biocel.2021.106100","key":"2026010210200889000_gutjnl-2025-336966v1.59","year":"2021","issue":null,"author":"Xin","volume":"141","first-page":"106100","unstructured":null,"article-title":"Methionine deficiency promoted mitophagy via lncRNA PVT1-mediated promoter demethylation of BNIP3 in gastric cancer","journal-title":"Int J Biochem Cell Biol","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41586-020-2682-1","key":"2026010210200889000_gutjnl-2025-336966v1.60","year":"2020","issue":null,"author":"Bian","volume":"585","first-page":"277","unstructured":null,"article-title":"Cancer SLC43A2 alters T cell methionine metabolism and histone methylation","journal-title":"Nature New Biol","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2019.01.252","key":"2026010210200889000_gutjnl-2025-336966v1.61","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/nu12030684","key":"2026010210200889000_gutjnl-2025-336966v1.62","year":"2020","issue":null,"author":"Wanders","volume":"12","first-page":null,"unstructured":null,"article-title":"Methionine Restriction and Cancer Biology","journal-title":"Nutrients","doi-asserted-by":"crossref"},{"DOI":"10.1073/pnas.73.5.1523","key":"2026010210200889000_gutjnl-2025-336966v1.63","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1207/S15327914NC381_17","key":"2026010210200889000_gutjnl-2025-336966v1.64","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ctrv.2012.01.004","key":"2026010210200889000_gutjnl-2025-336966v1.65","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"2026010210200889000_gutjnl-2025-336966v1.66","year":"1978","issue":null,"author":"Kreis","volume":"38","first-page":"2259","unstructured":null,"article-title":"Methionine requirement and replacement by homocysteine in tissue cultures of selected rodent and human malignant and normal cells","journal-title":"Cancer Res","doi-asserted-by":null},{"DOI":null,"key":"2026010210200889000_gutjnl-2025-336966v1.67","year":"1997","issue":null,"author":"Hoshiya","volume":"17","first-page":"4371","unstructured":null,"article-title":"Methionine-depletion modulates the efficacy of 5-fluorouracil in human gastric cancer in nude mice","journal-title":"Anticancer Res","doi-asserted-by":null},{"DOI":"10.1134/S0006297923070076","key":"2026010210200889000_gutjnl-2025-336966v1.68","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"2026010210200889000_gutjnl-2025-336966v1.69","year":"2000","issue":null,"author":"Cao","volume":"6","first-page":"255","unstructured":null,"article-title":"A study of preoperative methionine-depleting parenteral nutrition plus chemotherapy in gastric cancer patients","journal-title":"World J Gastroenterol","doi-asserted-by":null},{"DOI":"10.1007/978-1-4939-8796-2_8","key":"2026010210200889000_gutjnl-2025-336966v1.70","year":"2019","issue":null,"author":"Hoffman","volume":"1866","first-page":"83","unstructured":null,"article-title":"Dietary Methionine Restriction-Based Cancer Chemotherapy in Rodents","journal-title":"Methods Mol Biol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ccell.2020.04.005","key":"2026010210200889000_gutjnl-2025-336966v1.71","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pone.0049638","key":"2026010210200889000_gutjnl-2025-336966v1.72","year":"2013","issue":null,"author":"Basavanna","volume":"8","first-page":null,"unstructured":null,"article-title":"The Effects of Methionine Acquisition and Synthesis on Streptococcus Pneumoniae Growth and Virulence","journal-title":"PLoS ONE","doi-asserted-by":"crossref"},{"DOI":"10.1099/13500872-141-2-431","key":"2026010210200889000_gutjnl-2025-336966v1.73","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1046/j.1365-2958.2000.02150.x","key":"2026010210200889000_gutjnl-2025-336966v1.74","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0378-1135(03)00212-8","key":"2026010210200889000_gutjnl-2025-336966v1.75","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1128/IAI.72.6.3310-3314.2004","key":"2026010210200889000_gutjnl-2025-336966v1.76","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0065-2660(08)60357-0","key":"2026010210200889000_gutjnl-2025-336966v1.77","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/nrmicro.2017.66","key":"2026010210200889000_gutjnl-2025-336966v1.78","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.chom.2016.07.019","key":"2026010210200889000_gutjnl-2025-336966v1.79","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/nmeth.1923","key":"2026010210200889000_gutjnl-2025-336966v1.80","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ymeth.2016.02.020","key":"2026010210200889000_gutjnl-2025-336966v1.81","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.7717/peerj.7359","key":"2026010210200889000_gutjnl-2025-336966v1.82","year":"2019","issue":null,"author":"Kang","volume":"7","first-page":null,"unstructured":null,"article-title":"MetaBAT 2: an adaptive binning algorithm for robust and efficient genome reconstruction from metagenome assemblies","journal-title":"PeerJ","doi-asserted-by":"crossref"},{"DOI":"10.1093/bioinformatics/btac672","key":"2026010210200889000_gutjnl-2025-336966v1.83","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/nbt.3893","key":"2026010210200889000_gutjnl-2025-336966v1.84","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/bioinformatics/btm098","key":"2026010210200889000_gutjnl-2025-336966v1.85","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pcbi.1005595","key":"2026010210200889000_gutjnl-2025-336966v1.86","year":"2017","issue":null,"author":"Wick","volume":"13","first-page":null,"unstructured":null,"article-title":"Unicycler: Resolving bacterial genome assemblies from short and long sequencing reads","journal-title":"PLoS Comput Biol","doi-asserted-by":"crossref"},{"DOI":"10.1186/1471-2105-11-119","key":"2026010210200889000_gutjnl-2025-336966v1.87","year":"2010","issue":null,"author":"Hyatt","volume":"11","first-page":null,"unstructured":null,"article-title":"Prodigal: prokaryotic gene recognition and translation initiation site identification","journal-title":"BMC Bioinformatics","doi-asserted-by":"crossref"},{"DOI":"10.1007/978-1-4939-9173-0_1","key":"2026010210200889000_gutjnl-2025-336966v1.88","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/0378-1119(87)90278-2","key":"2026010210200889000_gutjnl-2025-336966v1.89","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pcbi.1009442","key":"2026010210200889000_gutjnl-2025-336966v1.90","year":"2021","issue":null,"author":"Mallick","volume":"17","first-page":null,"unstructured":null,"article-title":"Multivariable association discovery in population-scale meta-omics studies","journal-title":"PLoS Comput Biol","doi-asserted-by":"crossref"},{"DOI":"10.1093/molbev/msad235","key":"2026010210200889000_gutjnl-2025-336966v1.91","year":"2023","issue":null,"author":"Hall","volume":"40","first-page":null,"unstructured":null,"article-title":"Building Phylogenetic Trees From Genome Sequences With kSNP4","journal-title":"Mol Biol Evol","doi-asserted-by":"crossref"}],"short-title":[],"update-policy":"https://doi.org/10.1136/crossmarkpolicy","alternative-id":["10.1136/gutjnl-2025-336966"],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Gut"],"reference-count":91,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,2]]},"references-count":91,"short-container-title":["Gut"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1136/gutjnl-2025-336966","is_oa":false,"title":"Streptococcus anginosus\n -derived methionine promotes gastric cancer progression","updated":"2026-01-03T00:50:51+00:00","published_date":"2026-01-02","best_oa_location":null}},"created_at":"2026-01-11T11:19:33.869Z","updated_at":"2026-01-21T12:05:26.220Z","tags":[{"paper_doi":"10.1136/gutjnl-2025-336966","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1136/gutjnl-2025-336966","tag_type":"condition","value":"Gastric Cancer","value_numeric":null},{"paper_doi":"10.1136/gutjnl-2025-336966","tag_type":"warning","value":"No quantitative results are available in the supplied text.","value_numeric":null},{"paper_doi":"10.1136/gutjnl-2025-336966","tag_type":"warning","value":"Study design cannot be determined from the provided excerpt.","value_numeric":null},{"paper_doi":"10.1136/gutjnl-2025-336966","tag_type":"warning","value":"The abstract text is incomplete; key methods, sample size, and outcomes are not provided.","value_numeric":null}],"summaries":{"what_studied":"The study examined whether Streptococcus anginosus-derived methionine drives gastric cancer progression, using stool shotgun metagenomic functional profiles with subsequent verification experiments."}},{"doi":"10.1158/1078-0432.ccr-25-1982","pmid":"41283902","title":"Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach","journal_title":"Clinical Cancer Research","journal_issn":"1078-0432","published_at":"2025-11-24T00:00:00.000Z","url":"https://doi.org/10.1158/1078-0432.ccr-25-1982","source_score":42,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-12-28","doi":"10.1158/1078-0432.ccr-25-1982","days":"14","issn":"1078-0432","rank":"9","field":"Clinical Medicine","score":"42","category":"Oncology","categories":["Oncology"],"_categories":["Oncology"]},"pubmed":{"doi":"10.1158/1078-0432.CCR-25-1982","title":"Advances in Targeting HER2 across Cancer Subtypes - A Pan-tumor Approach.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","methods":"","results":"","abstract":"$35","keywords":[],"pubmed_id":"41283902","conclusions":"","publication_date":"2025-11-24T00:00:00"},"crossref":{"DOI":"10.1158/1078-0432.ccr-25-1982","URL":"https://doi.org/10.1158/1078-0432.ccr-25-1982","ISSN":["1078-0432","1557-3265"],"link":[{"URL":"https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-25-1982/3684681/ccr-25-1982.pdf","content-type":"application/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-25-1982/3715941/ccr-25-1982.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-25-1982/3715941/ccr-25-1982.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"OF1-OF31","type":"journal-article","issue":null,"score":1,"title":["Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach"],"author":[{"given":"Taiwo","family":"Adesoye","sequence":"first","affiliation":[{"name":"1Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}]},{"given":"Ecaterina E.","family":"Dumbrava","sequence":"additional","affiliation":[{"name":"2Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}]},{"given":"Kanwal P.S.","family":"Raghav","sequence":"additional","affiliation":[{"name":"3Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}]},{"given":"Aysegul A.","family":"Sahin","sequence":"additional","affiliation":[{"name":"4Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[{"name":"4Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}]},{"given":"Sunyoung S.","family":"Lee","sequence":"additional","affiliation":[{"name":"3Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}]},{"given":"Milind M.","family":"Javle","sequence":"additional","affiliation":[{"name":"3Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}]},{"given":"Shubham","family":"Pant","sequence":"additional","affiliation":[{"name":"2Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}]},{"given":"Omar","family":"Alhalabi","sequence":"additional","affiliation":[{"name":"5Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}]},{"given":"Xiuning","family":"Le","sequence":"additional","affiliation":[{"name":"6Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}]},{"given":"Vicente","family":"Valero","sequence":"additional","affiliation":[{"name":"7Division of Cancer Medicine, Department of Breast Medical Oncology, The University of MD Anderson Cancer Center, Houston, Texas."}]},{"given":"Paula R.","family":"Pohlmann","sequence":"additional","affiliation":[{"name":"2Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"7Division of Cancer Medicine, Department of Breast Medical Oncology, The University of MD Anderson Cancer Center, Houston, Texas."}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"name":"1Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}]}],"funder":[{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","award":["1UM1 TR0045906"],"award-info":[{"award-number":["1UM1 TR0045906"]}],"doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2025,12,17]]},"member":"1086","prefix":"10.1158","source":"Crossref","volume":null,"created":{"date-time":"2025-11-24T15:42:47Z","timestamp":1763998967000,"date-parts":[[2025,11,24]]},"indexed":{"date-time":"2025-12-17T14:31:17Z","timestamp":1765981877408,"date-parts":[[2025,12,17]]},"subject":[],"abstract":"$36","language":"en","relation":{},"resource":{"primary":{"URL":"https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-25-1982/770975/Advances-in-Targeting-HER2-across-Cancer-Subtypes"}},"subtitle":[],"deposited":{"date-time":"2025-12-17T14:26:18Z","timestamp":1765981578000,"date-parts":[[2025,12,17]]},"issn-type":[{"type":"print","value":"1078-0432"},{"type":"electronic","value":"1557-3265"}],"published":{"date-parts":[[2025,12,17]]},"publisher":"American Association for Cancer Research (AACR)","reference":null,"short-title":[],"update-policy":"https://doi.org/10.1158/crossmark_policy","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"original-title":[],"container-title":["Clinical Cancer Research"],"reference-count":0,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,17]]},"references-count":0,"short-container-title":[],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1158/1078-0432.ccr-25-1982","is_oa":false,"title":"Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach","updated":"2025-12-19T02:31:00+00:00","published_date":"2025-11-24","best_oa_location":null}},"created_at":"2026-01-11T11:19:33.869Z","updated_at":"2026-01-11T11:19:33.869Z","tags":[{"paper_doi":"10.1158/1078-0432.ccr-25-1982","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-1982","tag_type":"condition","value":"Biliary Tract Cancer","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-1982","tag_type":"condition","value":"Bladder Cancer","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-1982","tag_type":"condition","value":"Breast Cancer","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-1982","tag_type":"condition","value":"Colorectal Cancer","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-1982","tag_type":"condition","value":"Gastric Cancer","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-1982","tag_type":"condition","value":"Lung Cancer","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-1982","tag_type":"condition","value":"Ovarian Cancer","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-1982","tag_type":"modality","value":"Antibody-Drug Conjugate","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-1982","tag_type":"modality","value":"Bispecific Antibody","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-1982","tag_type":"modality","value":"Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-1982","tag_type":"modality","value":"Tyrosine Kinase Inhibitor","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-1982","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-1982","tag_type":"warning","value":"Design classification is based on the abstract; it is unclear whether the methods were systematic.","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-1982","tag_type":"warning","value":"No quantitative efficacy or safety outcomes or sample size are provided in the abstract.","value_numeric":null}],"summaries":{"what_studied":"A review of HER2-targeted treatment strategies across HER2-expressing solid tumors, covering clinical efficacy, adverse events, resistance mechanisms, heterogeneity of expression, biomarker-driven patient selection, and diagnostic tools.","limitations":"Narrative review without new primary data; the abstract provides no quantitative outcomes or pooled estimates.","practice_takeaway":"Accurate HER2 assessment and biomarker-driven selection are central when considering HER2-directed therapies across HER2-expressing solid tumors, with attention to adverse events and resistance highlighted in this review."}},{"doi":"10.1001/jamasurg.2025.4929","pmid":"41222957","title":"Laparoscopic vs Open Distal Gastrectomy With D2 Lymphadenectomy for Clinical T4a Gastric Cancer","journal_title":"JAMA Surgery","journal_issn":"2168-6254","published_at":"2025-11-12T00:00:00.000Z","url":"https://doi.org/10.1001/jamasurg.2025.4929","source_score":23,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-16","doi":"10.1001/jamasurg.2025.4929","days":"7","issn":"2168-6254","rank":"7","field":"Clinical Medicine","score":"23","category":"Surgery","categories":["Surgery"],"_categories":["Surgery"]},"pubmed":{"doi":"10.1001/jamasurg.2025.4929","title":"Laparoscopic vs Open Distal Gastrectomy With D2 Lymphadenectomy for Clinical T4a Gastric Cancer: The UMC-UPPERGI-01 Randomized Clinical Trial.","journal":"JAMA surgery","methods":"","results":"$37","abstract":"$38","keywords":[],"pubmed_id":"41222957","conclusions":"","publication_date":"2025-11-12T00:00:00"},"crossref":{"DOI":"10.1001/jamasurg.2025.4929","URL":"https://doi.org/10.1001/jamasurg.2025.4929","ISSN":["2168-6254"],"link":[{"URL":"https://jamanetwork.com/journals/jamasurgery/articlepdf/2841298/jamasurgery_dat_2025_oi_250075_1767031598.03318.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"9","type":"journal-article","issue":"1","score":1,"title":["Laparoscopic vs Open Distal Gastrectomy With D2 Lymphadenectomy for Clinical T4a Gastric Cancer"],"author":[{"given":"Tran Quang","family":"Dat","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Surgery, University Medical Center, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam"}]},{"given":"Dang Quang","family":"Thong","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, University Medical Center, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam"}]},{"given":"Doan Thuy","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, University Medical Center, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam"}]},{"given":"Nguyen Viet","family":"Hai","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, University Medical Center, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam"}]},{"given":"Tran Duy","family":"Phuoc","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, University Medical Center, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam"}]},{"given":"Nguyen Vu Tuan","family":"Anh","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam"}]},{"given":"Nguyen Hoang","family":"Bac","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, University Medical Center, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam"},{"name":"Department of General Surgery, Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam"}]},{"given":"Vo Duy","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, University Medical Center, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam"},{"name":"Department of General Surgery, Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam"}]}],"issued":{"date-parts":[[2026,1,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"161","created":{"date-time":"2025-11-12T16:00:33Z","timestamp":1762963233000,"date-parts":[[2025,11,12]]},"indexed":{"date-time":"2026-01-15T07:46:03Z","timestamp":1768463163820,"date-parts":[[2026,1,15]]},"subject":[],"abstract":"$39","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamasurgery/fullarticle/2841298"}},"subtitle":["The UMC-UPPERGI-01 Randomized Clinical Trial"],"deposited":{"date-time":"2026-01-14T16:01:05Z","timestamp":1768406465000,"date-parts":[[2026,1,14]]},"issn-type":[{"type":"print","value":"2168-6254"}],"published":{"date-parts":[[2026,1,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.3322/caac.21660","key":"soi250075r1","year":"2021","issue":"3","author":"Sung","volume":"71","first-page":"209","unstructured":null,"article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","journal-title":"CA Cancer J Clin","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10120-022-01331-8","key":"soi250075r2","year":"2023","issue":"1","author":"Japanese Gastric Cancer Association","volume":"26","first-page":"1","unstructured":null,"article-title":"Japanese gastric cancer treatment guidelines 2021 (6th edition).","journal-title":"Gastric Cancer","doi-asserted-by":"publisher"},{"DOI":"10.5230/jgc.2023.23.e11","key":"soi250075r3","year":"2023","issue":"1","author":"Kim","volume":"23","first-page":"3","unstructured":null,"article-title":"Korean practice guidelines for gastric cancer 2022: an evidence-based, multidisciplinary approach.","journal-title":"J Gastric Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(25)00052-2","key":"soi250075r4","year":"2025","issue":"10494","author":"Sundar","volume":"405","first-page":"2087","unstructured":null,"article-title":"Gastric cancer.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1007/s12029-024-01048-0","key":"soi250075r5","year":"2024","issue":"2","author":"Bittar","volume":"55","first-page":"652","unstructured":null,"article-title":"Laparoscopic versus open gastrectomy for advanced gastric cancer: a meta-analysis of randomized controlled trials.","journal-title":"J Gastrointest Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1155/2022/8324242","key":"soi250075r6","year":"2022","issue":null,"author":"Izumi","volume":null,"first-page":null,"unstructured":null,"article-title":"How to decide approaches and procedures for early and advanced gastric cancer?","journal-title":"Can J Gastroenterol Hepatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaoncol.2018.6727","key":"soi250075r7","year":"2019","issue":"4","author":"Kim","volume":"5","first-page":"506","unstructured":null,"article-title":"Effect of laparoscopic distal gastrectomy vs open distal gastrectomy on long-term survival among patients with stage I gastric cancer: the KLASS-01 randomized clinical trial.","journal-title":"JAMA Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ijsu.2018.05.733","key":"soi250075r8","year":"2018","issue":null,"author":"Zhang","volume":"56","first-page":"31","unstructured":null,"article-title":"Reevaluation of laparoscopic versus open distal gastrectomy for early gastric cancer in Asia: a meta-analysis of randomized controlled trials.","journal-title":"Int J Surg","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10120-016-0646-9","key":"soi250075r9","year":"2017","issue":"4","author":"Katai","volume":"20","first-page":"699","unstructured":null,"article-title":"Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer: Japan Clinical Oncology Group Study JCOG0912.","journal-title":"Gastric Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamasurg.2021.5104","key":"soi250075r10","year":"2022","issue":"1","author":"Huang","volume":"157","first-page":"9","unstructured":null,"article-title":"Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: five-year outcomes from the CLASS-01 randomized clinical trial.","journal-title":"JAMA Surg","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamasurg.2022.2749","key":"soi250075r11","year":"2022","issue":"10","author":"Son","volume":"157","first-page":"879","unstructured":null,"article-title":"Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: 5-year outcomes of the KLASS-02 randomized clinical trial.","journal-title":"JAMA Surg","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamasurg.2023.0096","key":"soi250075r12","year":"2023","issue":"5","author":"Etoh","volume":"158","first-page":"445","unstructured":null,"article-title":"Five-year survival outcomes of laparoscopy-assisted vs open distal gastrectomy for advanced gastric cancer: the JLSSG0901 randomized clinical trial.","journal-title":"JAMA Surg","doi-asserted-by":"publisher"},{"DOI":"10.3389/fmed.2021.767904","key":"soi250075r13","year":"2022","issue":null,"author":"Hu","volume":"8","first-page":null,"unstructured":null,"article-title":"Incidence, risk factors and prognosis of T4a gastric cancer: a population-based study.","journal-title":"Front Med (Lausanne)","doi-asserted-by":"publisher"},{"DOI":"10.1186/1477-7819-10-68","key":"soi250075r14","year":"2012","issue":null,"author":"Liu","volume":"10","first-page":"68","unstructured":null,"article-title":"Prognostic significance of tumor markers in T4a gastric cancer.","journal-title":"World J Surg Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12885-021-08767-8","key":"soi250075r15","year":"2021","issue":"1","author":"Yura","volume":"21","first-page":"1056","unstructured":null,"article-title":"The prognostic impact of macroscopic serosal change on resectable advanced gastric cancer.","journal-title":"BMC Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00464-018-6111-6","key":"soi250075r16","year":"2018","issue":"4","author":"Shibasaki","volume":"32","first-page":"2137","unstructured":null,"article-title":"Outermost layer-oriented medial approach for infrapyloric nodal dissection in laparoscopic distal gastrectomy.","journal-title":"Surg Endosc","doi-asserted-by":"publisher"},{"DOI":"10.1002/ags3.12398","key":"soi250075r17","year":"2020","issue":"6","author":"Washio","volume":"4","first-page":"618","unstructured":null,"article-title":"Postoperative pancreatic fistula after gastrectomy for gastric cancer.","journal-title":"Ann Gastroenterol Surg","doi-asserted-by":"publisher"},{"DOI":null,"key":"soi250075r18","year":"1994","issue":"5B","author":"Ikeguchi","volume":"14","first-page":"2131","unstructured":null,"article-title":"Relationship between area of serosal invasion and intraperitoneal free cancer cells in patients with gastric cancer.","journal-title":"Anticancer Res","doi-asserted-by":null},{"DOI":"10.1007/s00464-010-1235-3","key":"soi250075r19","year":"2011","issue":"2","author":"Du","volume":"25","first-page":"619","unstructured":null,"article-title":"Application of stereology to study the effects of pneumoperitoneum on peritoneum.","journal-title":"Surg Endosc","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13304-023-01476-w","key":"soi250075r20","year":"2023","issue":"6","author":"Illuminati","volume":"75","first-page":"1645","unstructured":null,"article-title":"Laparoscopy-assisted vs open total gastrectomy with D2 lymphadenectomy for advanced gastric cancer: results of a retrospective, multicenter study.","journal-title":"Updates Surg","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.suronc.2019.01.003","key":"soi250075r21","year":"2019","issue":null,"author":"Li","volume":"28","first-page":"167","unstructured":null,"article-title":"Surgical and long-term oncologic outcomes of laparoscopic and open gastrectomy for serosa-positive (pT4a) gastric cancer: a propensity score-matched analysis.","journal-title":"Surg Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ijsu.2017.01.116","key":"soi250075r22","year":"2017","issue":null,"author":"Zhang","volume":"41","first-page":"23","unstructured":null,"article-title":"Comparative study of laparoscopy-assisted and open radical gastrectomy for stage T4a gastric cancer.","journal-title":"Int J Surg","doi-asserted-by":"publisher"},{"DOI":"10.1097/SLE.0000000000000684","key":"soi250075r23","year":"2019","issue":"6","author":"Zhang","volume":"29","first-page":"476","unstructured":null,"article-title":"Long-term outcomes of laparoscopy-assisted gastrectomy for T4a advanced gastric cancer: a single-center retrospective study.","journal-title":"Surg Laparosc Endosc Percutan Tech","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12957-024-03422-5","key":"soi250075r24","year":"2024","issue":"1","author":"Pang","volume":"22","first-page":"143","unstructured":null,"article-title":"Laparoscopic versus open gastrectomy for nonmetastatic T4a gastric cancer: a meta-analysis of reconstructed individual participant data from propensity score-matched studies.","journal-title":"World J Surg Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1245/s10434-022-12897-z","key":"soi250075r25","year":"2023","issue":"4","author":"Long","volume":"30","first-page":"2278","unstructured":null,"article-title":"Long-term outcomes of open versus laparoscopic distal gastrectomy for T4a gastric cancer: a propensity score-matched cohort study.","journal-title":"Ann Surg Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1097/SLA.0000000000003217","key":"soi250075r26","year":"2019","issue":"6","author":"Lee","volume":"270","first-page":"983","unstructured":null,"article-title":"Short-term outcomes of a multicenter randomized controlled trial comparing laparoscopic distal gastrectomy with D2 lymphadenectomy to open distal gastrectomy for locally advanced gastric cancer (KLASS-02-RCT).","journal-title":"Ann Surg","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.surg.2020.11.032","key":"soi250075r27","year":"2021","issue":"6","author":"Long","volume":"169","first-page":"1486","unstructured":null,"article-title":"Laparoscopic versus open gastrectomy for serosa-invasive gastric cancer: a single-center retrospective cohort study.","journal-title":"Surgery","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ejso.2022.05.019","key":"soi250075r28","year":"2022","issue":"9","author":"Jeong","volume":"48","first-page":"1988","unstructured":null,"article-title":"Comparing surgical and oncologic outcomes between laparoscopic gastrectomy and open gastrectomy in advanced gastric cancer with serosal invasion: a retrospective study with propensity score matching.","journal-title":"Eur J Surg Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00423-021-02114-y","key":"soi250075r29","year":"2021","issue":"3","author":"Pang","volume":"406","first-page":"641","unstructured":null,"article-title":"Comparisons of perioperative and survival outcomes of laparoscopic versus open gastrectomy for serosa-positive (pT4a) gastric cancer patients: a propensity score matched analysis.","journal-title":"Langenbecks Arch Surg","doi-asserted-by":"publisher"},{"DOI":"10.1089/lap.2023.0074","key":"soi250075r30","year":"2023","issue":"8","author":"Kuwabara","volume":"33","first-page":"756","unstructured":null,"article-title":"Comparison of surgical and oncological outcomes of laparoscopic and open gastrectomy for pathologically serosa-invasive (pT4a) advanced gastric cancer-retrospective propensity score-matched analysis.","journal-title":"J Laparoendosc Adv Surg Tech A","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12893-025-02933-6","key":"soi250075r31","year":"2025","issue":"1","author":"Dat","volume":"25","first-page":"193","unstructured":null,"article-title":"Laparoscopic versus open distal gastrectomy with d2 lymphadenectomy in treatment of locally T4A gastric cancer: the protocol of a randomized controlled trial.","journal-title":"BMC Surg","doi-asserted-by":"publisher"},{"DOI":"10.1259/bjr.20130290","key":"soi250075r32","year":"2013","issue":"1029","author":"Kim","volume":"86","first-page":null,"unstructured":null,"article-title":"MDCT features in the differentiation of T4a gastric cancer from less-advanced gastric cancer: significance of the hyperattenuating serosa sign.","journal-title":"Br J Radiol","doi-asserted-by":"publisher"},{"DOI":"10.1245/s10434-017-5974-4","key":"soi250075r33","year":"2017","issue":"11","author":"Tsujiura","volume":"24","first-page":"3331","unstructured":null,"article-title":"“Pancreas-compressionless gastrectomy”: a novel laparoscopic approach for suprapancreatic lymph node dissection.","journal-title":"Ann Surg Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1097/SLA.0b013e3181b13ca2","key":"soi250075r34","year":"2009","issue":"2","author":"Clavien","volume":"250","first-page":"187","unstructured":null,"article-title":"The Clavien-Dindo classification of surgical complications: five-year experience.","journal-title":"Ann Surg","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10120-018-0839-5","key":"soi250075r35","year":"2019","issue":"1","author":"Baiocchi","volume":"22","first-page":"172","unstructured":null,"article-title":"International consensus on a complications list after gastrectomy for cancer.","journal-title":"Gastric Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.surg.2016.11.014","key":"soi250075r36","year":"2017","issue":"3","author":"Bassi","volume":"161","first-page":"584","unstructured":null,"article-title":"The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after.","journal-title":"Surgery","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00268-015-3160-z","key":"soi250075r37","year":"2015","issue":"11","author":"Inaki","volume":"39","first-page":"2734","unstructured":null,"article-title":"A multi-institutional, prospective, phase ii feasibility study of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for locally advanced gastric cancer (JLSSG0901).","journal-title":"World J Surg","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2015.63.7215","key":"soi250075r38","year":"2016","issue":"12","author":"Hu","volume":"34","first-page":"1350","unstructured":null,"article-title":"Morbidity and mortality of laparoscopic versus open D2 distal gastrectomy for advanced gastric cancer: a randomized controlled trial.","journal-title":"J Clin Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1097/SLA.0000000000001346","key":"soi250075r39","year":"2016","issue":"1","author":"Kim","volume":"263","first-page":"28","unstructured":null,"article-title":"Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01).","journal-title":"Ann Surg","doi-asserted-by":"publisher"},{"DOI":"10.1245/s10434-023-13967-6","key":"soi250075r40","year":"2023","issue":"12","author":"Tsekrekos","volume":"30","first-page":"7196","unstructured":null,"article-title":"Impact of laparoscopic gastrectomy on the completion rate of the perioperative chemotherapy regimen in gastric cancer: a Swedish nationwide study.","journal-title":"Ann Surg Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1097/MD.0000000000023795","key":"soi250075r41","year":"2020","issue":"51","author":"Jiao","volume":"99","first-page":null,"unstructured":null,"article-title":"Recurrence pattern and its predictors for advanced gastric cancer after total gastrectomy.","journal-title":"Medicine (Baltimore)","doi-asserted-by":"publisher"},{"DOI":"10.1002/jso.25834","key":"soi250075r42","year":"2020","issue":"3","author":"Farrow","volume":"121","first-page":"486","unstructured":null,"article-title":"Impact of minimally invasive gastrectomy on use of and time to adjuvant chemotherapy for gastric adenocarcinoma.","journal-title":"J Surg Oncol","doi-asserted-by":"publisher"},{"DOI":"10.3748/wjg.v26.i14.1594","key":"soi250075r43","year":"2020","issue":"14","author":"Nakanishi","volume":"26","first-page":"1594","unstructured":null,"article-title":"Is the measurement of drain amylase content useful for predicting pancreas-related complications after gastrectomy with systematic lymphadenectomy?","journal-title":"World J Gastroenterol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10120-017-0764-z","key":"soi250075r44","year":"2018","issue":"1","author":"Hiki","volume":"21","first-page":"162","unstructured":null,"article-title":"Higher incidence of pancreatic fistula in laparoscopic gastrectomy. real-world evidence from a nationwide prospective cohort study.","journal-title":"Gastric Cancer","doi-asserted-by":"publisher"},{"DOI":"10.5230/jgc.2018.18.e15","key":"soi250075r45","year":"2018","issue":"2","author":"Ida","volume":"18","first-page":"134","unstructured":null,"article-title":"Pancreatic compression during lymph node dissection in laparoscopic gastrectomy: possible cause of pancreatic leakage.","journal-title":"J Gastric Cancer","doi-asserted-by":"publisher"},{"DOI":"10.5230/jgc.2013.13.1.19","key":"soi250075r46","year":"2013","issue":"1","author":"Uyama","volume":"13","first-page":"19","unstructured":null,"article-title":"Laparoscopic surgery for advanced gastric cancer: current status and future perspectives.","journal-title":"J Gastric Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00464-011-1792-0","key":"soi250075r47","year":"2011","issue":"12","author":"Kanaya","volume":"25","first-page":"3928","unstructured":null,"article-title":"Video: laparoscopy distinctive technique for suprapancreatic lymph node dissection: medial approach for laparoscopic gastric cancer surgery.","journal-title":"Surg Endosc","doi-asserted-by":"publisher"},{"DOI":"10.3748/wjg.v22.i19.4626","key":"soi250075r48","year":"2016","issue":"19","author":"Suda","volume":"22","first-page":"4626","unstructured":null,"article-title":"Minimally invasive surgery for upper gastrointestinal cancer: our experience and review of the literature.","journal-title":"World J Gastroenterol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamasurg.2021.3182","key":"soi250075r49","year":"2021","issue":"10","author":"Ojima","volume":"156","first-page":"954","unstructured":null,"article-title":"Short-term outcomes of robotic gastrectomy vs laparoscopic gastrectomy for patients with gastric cancer: a randomized clinical trial.","journal-title":"JAMA Surg","doi-asserted-by":"publisher"},{"DOI":"10.1097/SLA.0000000000004466","key":"soi250075r50","year":"2021","issue":"5","author":"Lu","volume":"273","first-page":"858","unstructured":null,"article-title":"Assessment of robotic versus laparoscopic distal gastrectomy for gastric cancer: a randomized controlled trial.","journal-title":"Ann Surg","doi-asserted-by":"publisher"},{"DOI":"10.1097/JS9.0000000000001826","key":"soi250075r51","year":"2024","issue":"12","author":"Li","volume":"110","first-page":"8045","unstructured":null,"article-title":"Efficacy and safety of robotic vs. laparoscopic gastrectomy for patients with gastric cancer: systematic review and meta-analysis.","journal-title":"Int J Surg","doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Surgery"],"published-print":{"date-parts":[[2026,1,1]]},"reference-count":51,"published-online":null,"references-count":51,"short-container-title":["JAMA Surg"],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1001/jamasurg.2025.4929","is_oa":true,"title":"Laparoscopic vs Open Distal Gastrectomy With D2 Lymphadenectomy for Clinical T4a Gastric Cancer","updated":"2025-11-14T00:12:00+00:00","published_date":"2025-11-12","best_oa_location":{"url":"https://jamanetwork.com/journals/jamasurgery/articlepdf/2841298/jamasurgery_dat_2025_oi_250075_1762802246.93521.pdf","pmh_id":null,"url_for_pdf":"https://jamanetwork.com/journals/jamasurgery/articlepdf/2841298/jamasurgery_dat_2025_oi_250075_1762802246.93521.pdf","url_for_landing_page":"https://doi.org/10.1001/jamasurg.2025.4929"}}},"created_at":"2026-01-18T22:40:12.285Z","updated_at":"2026-01-21T12:05:26.220Z","tags":[{"paper_doi":"10.1001/jamasurg.2025.4929","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2025.4929","tag_type":"category","value":"Surgery","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2025.4929","tag_type":"condition","value":"Gastric Cancer","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2025.4929","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2025.4929","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2025.4929","tag_type":"modality","value":"Surgery","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2025.4929","tag_type":"sample_size","value":"n=208","value_numeric":208},{"paper_doi":"10.1001/jamasurg.2025.4929","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2025.4929","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2025.4929","tag_type":"warning","value":"Noninferiority margin and statistical confirmation for noninferiority were not provided in the excerpt.","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2025.4929","tag_type":"warning","value":"Outcomes are limited to 30-day results; long-term oncologic endpoints were not reported.","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2025.4929","tag_type":"warning","value":"Single-center trial with procedures by qualified surgeons may limit generalizability to other settings.","value_numeric":null}],"summaries":{"what_studied":"A single-center, open-label, noninferiority randomized trial compared laparoscopic vs open distal gastrectomy with D2 lymphadenectomy in adults with clinical T4a gastric cancer. Short-term surgical and recovery outcomes through 30 days were assessed in 208 patients randomized 1:1.","key_result":"Thirty-day any postoperative complications were similar (22.1% [LDG] vs 21.2% [ODG]; P=.87) and severe complications were rare and comparable (2.9% vs 3.8%; P>.99). LDG had longer mean operative time (220.0 vs 153.7 minutes; P<.001) and higher median blood loss (80 vs 50 mL; P=.003), with no differences in time to first flatus, oral intake, hospital stay, or time to adjuvant chemotherapy; comorbidity increased complication risk (OR 2.42; 95% CI, 1.11-5.30; P=.03).","limitations":"Single-center, open-label design; only short-term outcomes are reported with long-term oncologic results pending; procedures were performed only by qualified surgeons, which may limit generalizability.","practice_takeaway":"For clinical T4a gastric cancer, laparoscopic distal gastrectomy achieved similar 30-day morbidity and mortality to open surgery when done by qualified surgeons, though with longer operative time and more blood loss. LDG can be considered an alternative to ODG where expertise exists, and clinicians should factor comorbidity into perioperative risk."}}],"initialOffset":18,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Gastric Cancer"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Gastric Cancer"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Gastric Cancer"}}}]]

Papers